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ABSTRACT
Brucellosis, a zoonotic disease caused by Brucella spp., presents both health and
economic difficulties for livestock, wildlife, and humans. While brucellosis is nearly
eradicated in the United States, the disease remains detrimental in many countries
worldwide.
Attempts to produce a safe and effective small ruminant vaccine have been met
with limited success. The current vaccine for bovine brucellosis in the United States is B.
abortus RB51. This strain transiently colonizes the host and induces a cell-mediated
immune response. Levels of protection have not been demonstrated in goats and thus it is
considered a relatively poor caprine vaccine that probably does not survive long enough
in the tissues to produce a sufficient protective immune response.
This study analyzes the possibility of using RB51 containing plasmid QAE for
vaccination in goats. The plasmid QAE contains a gene region of DNA from B.
melitensis 16M hypothesized to encode for a putative hemagglutinin that is believed to be
a host specificity protein. The region E gene sequence is not present in any strain of B.
abortus, including RB51. It is proposed that the addition of region E to RB51 will
enhance survivability in the caprine host to the extent where an adequate protective
immune response is elicited.
The QAE plasmid was electroporated into B. abortus RB51 and screened using
ampicillin resistance as a selective measure. Ten goats were conjunctivally inoculated
with RB51-QAE, the modified strain, and ten goats received strain RB51 in the same
manner as controls. Two goats from each group were euthanized and necropsied at
weekly intervals for four weeks and again at 42 days. Tissues from these animals were
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taken at necropsy and used to collect data for colonization and histopathology. Serum
samples were also analyzed for Brucella-specific antibodies. Both strains transiently
colonized the hosts without producing any detrimental pathology. However, the RB51QAE goats demonstrated higher levels of colonization and greater humoral immune
responses for longer periods of time. These are very promising findings as the levels of
colonization and humoral responses may correspond with better protection. These results
warrant further testing of RB51-QAE as a potential vaccine for caprine brucellosis.
The putative hemagglutinin was characterized using hemagglutination assays,
absorption assays, and mass spectrometry analysis following 2D gel electrophoresis. The
region E protein was found to provide RB51-QAE with increased hemagglutinating and
immunogenic capabilities. Furthermore, there is evidence to suggest that the protein is a
cell surface protein, not excreted from the cell.
The accepted gold standard for the detection of brucellae is bacterial culture.
PCR is being evaluated as a possible alternative detection method for Brucella spp. in
bodily fluids such as blood and urine. Currently, there is no accepted standard for
detection of brucellae using PCR.
The effects of template preparation, primer selection, and PCR optimization on
the limit of detection for B. abortus 2308 and B. melitensis 16M in association with
whole blood, plasma, or urine were examined. Ten-fold dilutions were made from a
known number of bacterial cells in each of the fluids tested. The practices of using whole
killed cells as a direct template for PCR as well as two differing DNA isolation
techniques were evaluated for each fluid dilution. Our findings suggest that a more
extensive template preparation technique and PCR protocol elongation can greatly
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improve the limit of detection capabilities. Biological fluids provided dissimilar results
based on the PCR inhibition properties of the fluid and DNA isolation techniques. The
results of this experiment encourage further investigation into the optimization of
conventional PCR techniques as a faster and more efficient diagnostic tool for Brucella
spp. in humans and animals.
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INTRODUCTION
Brucellae are aerobic, Gram-negative, facultative intracellular pathogens that are
the causative agents of brucellosis in both humans and animals. Brucella abortus is
responsible for bovine brucellosis and in other primary hosts such as moose, elk, and
bison. Secondary hosts of B. abortus include goats, sheep, pigs, and humans. Brucella
melitensis is the most virulent Brucella spp. and infects mainly goats, although humans
are a secondary host. Other species of Brucella include B. suis, B. ovis, and B. canis.
These species infect pigs, sheep, and dogs, respectively, as primary hosts. A recently
proposed species, B. microti, infects voles and foxes and is genetically homologous to
other species of brucellae. There are also two species, B. ceti and B. pinnipedialis, found
to infect marine mammals as primary hosts and current research suggests that both are
zoonotic pathogens (Foster et al. 2007). Three species, B. melitensis, B. abortus, and B.
suis, are considered agents of bioterrorism by the United States Centers for Disease
Control and Prevention because they are easily disseminated, highly contagious, and
stable under conditions of production and storage. Widespread disease would pose a
threat to public health for humans and companion animals, and have devastating effects
on the agricultural industry.
Transmission among animals is most often through direct contact of contaminated
substances with the mucous membranes. Human infection occurs through direct contact
with infected animals and the consumption of their unpasterurized dairy products. The
disease is not transmitted from human to human. Other modes of transmission can occur
through contact with abraded skin and aerosolization. Once in a susceptible host,
brucellae eventually disseminate throughout the host, colonizing tissues and affecting
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several systems detrimentally. Human brucellosis is primarily characterized by
undulating fever. Animal brucellosis is characterized by abortions and other pathologies
of the reproductive organs, as well as joint abnormalities.
Standard diagnosis of Brucella infection is performed by blood testing and
culture. Serologic diagnosis is not foolproof and can provide false positive results due to
antibodies produced by smooth vaccine strains or other bacteria with homologous
antigenic determinants. Bacterial culture is a long process and brucellosis may not be
correctly diagnosed for several days to weeks following sample collection. Furthermore,
a faster, more efficient, and reliable diagnostic method would improve the detection and
treatment capabilities of brucellosis in both humans and animals.
Complete genomic sequences have been published for several species of Brucella,
which have been essential in the discovery and characterization of virulence factors
employed by the organism under both in vitro and in vivo conditions. This study focuses
on the characterization of a putative hemagglutinin gene, named region E, located on the
chromosome of B. melitensis 16M that is absent in all strains of B. abortus (Perry 2007).
Protein characterization was performed under both in vitro conditions and in vivo in the
caprine model comparing a vaccine strain of B. abortus RB51 to a strain containing the
putative hemagglutinin gene expressed in trans, B. abortus RB51-QAE. These
experiments were carried out for the purpose of characterizing the region E putative
hemagglutinin and evaluating its potential role in the development of a more effective
rough vaccine. Rough vaccines are not highly effectual in small ruminants and the
development of a more efficacious vaccine would contribute tremendously to the
eradication efforts in endemic countries.
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PCR has been explored as an improved technique for the diagnosis of brucellosis
in humans and animals. There is currently no standardized technique for brucellae and
findings have been mixed. This study explored the limit of detection of Brucella cells by
conventional PCR in several easily-attainable bodily fluids to explore the possibility of
using PCR as a standard diagnostic tool for brucellosis.
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LITERATURE REVIEW
Genus Brucella
Bacteria in the genus Brucella are the causative agents of brucellosis in humans
and animals. Brucella spp. are important zoonotic and agricultural pathogens that infect
a wide range of hosts with varying degrees of pathology. Although rare in the United
States, brucellosis in both humans and animals remains a threat to public health and
agricultural economy in endemic areas.
Human brucellosis is uncommon in the United States with an estimated 100 cases
annually. The disease poses more serious problems in underdeveloped countries around
the world (Sauret et al. 2002, Seleem et al. 2009). Affected regions worldwide include
Latin America, southern Europe, the Middle East, areas in Asia and Africa, and countries
of the former Soviet Union. Classical species of Brucella that are infectious to humans
include B. melitensis (biovars 1-3), B. abortus (biovars 1-6, 9), and B.suis (biovars 1,3,4).
B. canis infections occur in immunocompromised individuals, but only rarely. There is
no approved vaccine for protection in humans and vaccines approved for use in animals
are infectious to humans. Transmission is most commonly through ingestion of
unpasteruized milk from an infected animal, direct contact with infected birth materials,
or during slaughter. Infection of humans is also possible through the aerosol route
(Heymann 2004, Smither et al. 2009). Although a reportable disease in most countries, it
is believed that the actual number of reported cases worldwide represents only a portion
of the actual cases (Sauret et al. 2002, Seleem et al. 2009).
Brucellosis is nearly eradicated in domestic animals in the United States through a
system of successful vaccination regimes and diagnostic testing procedures. Currently,
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domestic livestock in the United States are routinely tested for brucellosis using
standardized diagnostic procedures, such as the Rose Bengal and the Plate Agglutination
test, which are used to screen domestic herds (Robinson 2003). Those animals found to
be brucellosis suspects are subjected to further testing, and if confirmed positive, are
slaughtered for removal from the herd population (USDA 2006). Additional serological
tests are then conducted periodically following the removal of brucellosis seropositive
animals until the herd is considered completely negative (Ragan 2002). Prevention by
vaccination is a key tool in the eradication of brucellosis through preventative measures
and is implemented in domestic herds in the United States (USDA 2006). The current
vaccine used in the United States is the B. abortus RB51 rough vaccine, which replaced
the B. abortus Strain 19 (S19) smooth vaccine in 1996 following complications in
diagnostic testing with S19 (USDA 1996).
Continued herd management is crucial in the eradication program. Herd
management procedures assess the risk of a herd becoming exposed to and acquiring
brucellosis, implementing measures to reduce that risk, and perform routine testing to
ensure early detection (USDA 2008). Domestic livestock, especially those herds located
in areas that are high-risk for exposure, are routinely tested and closely monitored for any
signs of brucellosis and the occurrence of any abortions are thoroughly investigated.
Herds found to include brucellosis positive animals are quarantined until further testing
clears the herd of any suspect infections. Furthermore, any additions to a herd are tested
and confirmed brucellosis negative before entering the population (USDA 2006). The
control measures of this eradication program have proven successful in eliminating the
disease from domestic livestock in the United States (USDA 2008).
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Because it is more difficult to test wild animals, the status of brucellosis in
wildlife is not fully understood. Specifically, free-ranging elk and bison in the Greater
Yellowstone Area (GYA) pose the greatest obstacle to complete eradication in the United
States. Feed grounds have been developed where grazing herds of possibly infected wild
and domestic animals frequently congregate and intermingle. Because brucellosis is
spread primarily through contact with the fluid secretions, such as mucus, milk, maternal
and fetal tissues and other byproducts of abortion, one infected animal can quickly infect
several grazing herds through contact or exposure at a single feeding ground. Studies
have shown that fluids from infected animals that are deposited on the ground can remain
infective to other animals for periods of over 100 days, given the sample is in a cold,
shaded environment (Timoney et al. 1988).
B. melitensis, B. abortus, and B. suis are designated as class B, biosafety level 3
select agents by the Centers for Disease Control and Prevention. These species are
infectious to humans and are easily disseminated for potential weaponization (Pappas et
al. 2006). Brucellosis as a bioterrorist agent has the potential to cause devastating
consequences for agricultural and public health systems.
Brucella spp. are Gram-negative, non-motile, non-encapsulated coccobacilli that
are the causative agents of brucellosis in animals and humans (Corbel 1997). Most, but
not all, species express a complete lipopolysaccharide (LPS) outer membrane component.
The LPS provides protection from certain host defenses and structural support. The
outermost fraction of the LPS is the O-polysaccharide group (OPS) which
compositionally unique in Brucella spp. and highly antigenic. Species of Brucella that
express a functional OPS group are designated as “smooth”, whereas species that do not
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express a functional OPS group are designated “rough”. Ideal laboratory growth of
brucellae is performed with selective, nutrient-enriched media in an aerobic 5% CO2
atmosphere at 37°C over a period of 48-72 hours. Most classical species of brucellae
provide a positive reaction for catalase, oxidase, and urease tests, with the exception of B.
ovis, which is oxidase and urease negative, and B. neotomae, which is oxidase negative
(Yagupsky et al. 2005).
Pathology
Once an animal or individual becomes infected with the Brucella pathogen, the
bacterium travel in the lymph to the nearest draining lymph node and then into the blood
stream of the host animal. Brucella spp. avoid destruction by the host’s innate immune
system with an ability to avoid lysosomal degradation after being engulfed by host
macrophages (Celli 2006). Furthermore, Brucella spp. thrive and proliferate inside of the
host macrophage, and ultimately cause the death of that macrophage, releasing the
multiplied bacteria back into host tissues. Once the host becomes bacteremic, the
pathogen migrates throughout the body to different organs and tissues (Cheers et al.
1984).
The most common pathology of brucellosis in animals is the abortion of the first
pregnancy that occurs after the onset of the disease. Most Brucella spp. proliferate
efficiently in the cells of the body with high erythritol levels, such as the cells found in
the urinary and reproductive tracts (Enright 1990). Once in the uterus, the bacteria can
penetrate the epithelial cells of the embryonic membrane and cause placentitis, which can
lead to a decrease in the blood supply to the fetus. Fetuses recovered from brucella
infected mothers have also been shown to develop edema and congestion in their lungs
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and hemorrhages in their epicardium. Whether the cause is a decrease in oxygenated
blood due to an inflamed placenta or the detrimental lesions formed by the infection of
the fetus, the final outcome of pregnancy is either an abortion or a weak fetus that dies
shortly after birth (Enright 1990).
Other effects on the reproductive system of animals with brucellosis include the
swelling of the testes and epididymus of male animals. As in the uterus, Brucella in the
male urogenital tract can also cause inflammation and swelling of the male reproductive
organs. Orchitis and epididymitis are common symptoms of brucellosis in animals,
causing sterility in infected males. Most, if not all, Brucella species can be isolated from
semen, and males can shed the bacterium for prolonged periods (Iowa 2009). Brucellosis
is also responsible for arthritis of the joints and spondylitis in many infected animals as
well as hygroma formation on the knees. Brucellosis can also be responsible for mastitis
in females, neurologic swelling and splenic abscesses with edema, congestion, and
hemorrhage in the lung and heart.
Granulomatous inflammation is also observed during persistent Brucella
infections. The exudate of granulomatous inflammation is generally composed of mature
macrophages, which gravitate to the area of the body affected by the causative agent
(McLaughlin 2007). Here, macrophages have the potential to form into multinucleate
giant cells. Multinucleate giant cells are a hallmark of infections involving pathogens
that thrive within phagocytes, as infected macrophages are identified and engulfed by
other macrophages in a process that results in the formation of a giant cell composed of
several responding phagocytes (McLaughlin 2007, Abbas 2005). Fibrosis and necrosis
are often associated with granulomatous inflammation, especially in the case of
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granuloma formation. Granuloma formation is primarily a product of chronic delayedtype hypersensitivity and occurs in cases of chronic brucellosis. In a persistent infection
and subsequent immune response, the lytic and anti-pathogenic actions of non-specific
phagocytes begin to damage host tissue. In a chronic infection, this is sometimes
manifested as the formation of fibrosis and scar tissue surrounding the site of
inflammation, which has the potential to cause tissue damage that may disrupt normal
tissue function (Merck 2007). Necrosis formation in the center of granulomas may occur
due to anoxic conditions and may function to eliminate infected macrophages, destroying
the pathogen within (Abbas 2005).
Species of Brucella
Brucella melitensis
Originally named “Micrococcus melitensis”, Brucella melitensis was discovered
by Lieutenant Colonel David Bruce in 1887 from British soldiers residing in Malta.
Brucella melitensis is a world-wide disease which remains most problematic in
developing countries. Although considered to be eradicated in the United States, B.
melitensis is a continuing cause for concern because of its status as a potential agent of
biological warfare (Moreno et al. 2002).
The primary host of B. melitensis is the caprine host as well as the ovine host,
although the pathogen can be problematic in cattle, camels, and humans as secondary
hosts (Nielson et al. 1990). In female goats and sheep the primary symptom is abortion,
but larger doses of the pathogen cause mastitis and joint problems. In male goats,
orchitis is uncommon, and if observed it is generally unilateral. In male sheep, however,
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the disease is often asymptomatic, although orchitis and hygromas are a rare observation
(Alton 1990).
The only approved vaccine against B. melitensis is the Rev.1 vaccine, developed
from a laboratory strain of B. melitensis 16M. This vaccine, although effective, is
potentially abortigenic and produces anti-LPS antibodies that can interfere with
diagnostic tests (Gonzalez et al. 2008, Blasco 2006). Vaccines developed from strains of
B. abortus are not effective in providing protection against infection with B. melitensis.
B. melitensis is the most virulent strain in human infection, with only 1-10
organisms needed for infection and with undulant fever as the primary symptom (Mantur
et al. 2007). There is no human vaccine for brucellosis and the B. melitensis Rev.1
vaccine for animals is infectious to humans (Seleem et al. 2009). Brucella melitensis is
highly contagious and can be easily disseminated with devastating effects to public and
agricultural health. B. melitensis, as well as B. suis and B. abortus, have been deemed
potential bioterrorism agents by the United States Centers for Disease Control and
Prevention.
Brucella abortus
Brucella abortus is the agent responsible for the majority of bovine brucellosis
cases. It was discovered in 1897 by Bernhard Bang and the disease was originally called
“Bang’s disease” (Mochman et al. 1988). In 1918 Alice Evans linked B. abortus with the
previously discovered B. melitensis and showed that both were agents of brucellosis in
humans and animals (Parascandola 1998). Brucella abortus is distributed worldwide and
is still somewhat problematic in the United States, with wildlife remaining the most
prevalent reservoir.
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Primary hosts include cattle, bison and elk, but goats, sheep, pigs, and humans are
also susceptible as secondary hosts. Affected cattle typically experience a permanent
infection, shedding the bacterium for the duration of their lives (Nielson et al. 1990). The
disease is spread easily through direct contact and an entire herd can quickly become
compromised with the inclusion of a single infected animal. Bovine brucellosis is a
disease that primarily targets the reproductive system of cattle (Enright 1990). Infected
cows typically experience joint ailments, a decrease in milk production, sterility, and
abortion of the first pregnancy that occurs after the onset of infection (Nielson et al.
1990). In bulls, orchitis can develop. Although rare in the United States in domestic
cattle today, B. abortus remains a threat to wildlife species such as moose, elk, caribou,
and bison.
Brucella abortus in wildlife, particularly in the Greater Yellowstone area (GYA),
is difficult to control and monitor. The presence of brucellosis in the GYA was first
described in 1917 and it has persisted in Yellowstone bison and elk herds ever since.
Domestic cattle in and around the GYA may contract brucellosis from these reservoirs
(Davis and Elzer 2002). For this reason, the prevalence of brucellosis in free-ranging
wildlife of the GYA has proven to be a major hindrance in efforts to eradicate the disease
completely in the United States. Management practices implemented for the eradication
of brucellosis in domestic herds are not as easily applied to wildlife. Diagnostic testing
and removal of infected animals are difficult due to the relative inaccessibility of animals
and migration through multiple management jurisdictions (Etter and Drew 2006).
Vaccines developed for use in domestic livestock have shown a lesser effectiveness in
wildlife and present difficulties in terms of vaccine delivery (Davis and Elzer 2002).
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Vaccination against B. abortus has proven an important tool in eradication of the
disease. The first brucellosis vaccine approved for commercial use was labeled Strain 19
(S19) and was derived from a field strain of B. abortus (Sanmartino 2005). However,
S19 is a smooth organism and induces the production of antibodies that interfere with
diagnostic tests. For this reason, a rough B. abortus vaccine, termed RB51, was
developed from a laboratory strain of B. abortus 2308 and was shown to be equally
efficacious as S19 and did not hinder serological testing (Schurig 2002, 1991). RB51
remains the only approved vaccine against B. abortus in the United States.
Humans, although not a primary host, can contract brucellosis through contact
with infected animals. Brucella abortus is moderately infectious to humans, with an
estimated 1 × 105 organisms needed for infection and the primary symptom is undulant
fever. While B. melitensis is a more frequent and wide-spread zoonosis, B. abortus
infects mainly occupational groups working closely with the organism or infected
animals (Seleem et al. 2009). Brucella abortus vaccines approved for use in animals,
such as S19 and RB51, are infectious to humans and there remains no vaccine available
for human use against B. abortus. The largest economic and sociological threat from B.
abortus is to that of the cattle industry, where it is capable of severe economic damage.
Brucella suis
Swine brucellosis was first reported in 1914 in a government report by Traum
(Traum 1914) and was assumed to be caused by a strain of B. abortus. It was not until
1929 that the disease pathogen was recognized as closely-related, yet separate from B.
abortus and renamed B. suis, denoting the primary host (Huddleson, 1929). Brucella suis
maintains a serious presence in feral swine and has not been eradicated from domestic
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swine in the United States. All states, with the exception of Texas, maintained a swinebrucellosis-free status as of 2008 (USDA 2008), but Florida and Hawaii remain
problematic areas. The intermingling of domestic swine with a largely infected feral
swine population poses an obstacle in eradication of the disease from commercial swine
herds.
Brucella suis is most often described in pigs, but reindeer are also a primary host
for B. suis biovar 4. Secondary hosts include cattle, horses, dogs, and humans.
Transmission is most often accomplished through direct contact with the reproductive
byproducts of infected sows. An additional aspect of B. suis transmission is that the
organism can also be transmitted venereally from infected boars (Alton 1990). The
disease in swine is similar pathogenically to brucellosis in other animals. The most
common symptom is the incidence of abortions in pregnant females, but other symptoms
unrelated to the reproductive organs may occur, such as pain in the joints and spondylitis
(Conger et al. 1999). Brucella suis often presents a prolonged bacteremic phase in swine
which can last up to 34 weeks (Alton 1990). Brucella infected herds of reindeer have
been recorded across the northernmost regions of North America, with the majority of
infections occurring in the Arctic Circle (Zarnke 2001, Tessaro et al. 1986). There are
currently no vaccines derived from any B. suis strain and no commercially available
vaccine against B. suis infection for humans or animals in the United States. Studies
focused on the development of an effective B. suis vaccine are ongoing.
B. suis is moderately to highly infectious to humans, requiring contact with
approximately 1×103-1×104 organisms for infection. Because of the lengthy bacteremic
phase seen in swine, people working with infected pigs are at a higher risk of contracting
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brucellosis than those working with other animals (Conger et al. 1999). The highest risk
for contracting brucellosis through B. suis is seen in people working in close proximity
with the pathogen or infected animals. Undulant fever remains the primary symptom in
individuals infected with B. suis. This pathogen was weaponized via the M33 cluster
bomb by the United States in 1955 and all known US stocks were destroyed by the mid1990s (Smart 2008, Croddy et al. 2005).
Brucella ovis
Brucella ovis was originally described in New Zealand and Australia by
McFarland et al. and Simmons et al., respectively (Blasco 1990). Brucella ovis is most
prevalent in areas associated with sheep farming and cases have been recorded in New
Zealand, Australia, North and South America, South Africa, and several European
countries (Iowa 2009). Brucella ovis differs from the previously discussed species in that
it is a naturally rough strain that is infectious even without an intact lipopolysaccharide
(LPS), which lacks the O-polysaccharide side chain (OPS) (Buddle 1956). Other
differences are noted in biochemical tests in that B. ovis is found to be oxidase and urease
negative, whereas B. melitensis, B. abortus, and B. suis are positive for both.
Brucella ovis primarily infects rams while ewes and goats serve as other hosts for
the organism. This pathogen has also been documented to infect farmed red deer in New
Zealand. Transmission is often venereal and ewes carry the pathogen vaginally for two
months or more and shed the bacterium in their vaginal discharges and milk. Infected
rams have been shown to shed the bacterium in semen for up to 4 years or longer and
shedding in the urine has also been documented (Iowa 2009, Cerri et al. 1999). As with
other previously discussed species, direct contact with infected mucus membranes is
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another route of transmission. The incubation period in rams is as long as 3-8 weeks
post-inoculation. Symptoms of B. ovis in rams include orchitis, epididymitis, and
impaired fertility or sterility. Ewes are less likely to show symptoms if infected, but
infrequent abortions and placentitis can occur (Iowa 2009, Grillo et al. 1999).
There are no vaccine regimens practiced for protection of rams against B. ovis in
the United States. New Zealand employs a commercially available vaccine and most
applicable countries vaccinate young rams with B. melitensis Rev.1 (Iowa 2009, Jimenez
et al. 1994). Preliminary studies using mutant forms of the Rev.1 vaccine in sheep for
protection to B. ovis challenge infection have been documented (Grillo et al. 2008). The
test and slaughter method is used commonly to rid herds of infection. Antibiotic
treatment has been attempted in valuable rams but generally is not feasible for treatment
of a herd. B. ovis is not infectious to humans and although potentially detrimental to the
sheep industry, not considered a bioterrorist threat.
Brucella canis
Brucella canis was first described by Carmichael and Bruner in 1968 and is the
cause of brucellosis in dogs and other canids. The disease became of interest after a large
number of abortions were noted in beagles in 1966 (Morisette 1969). Geographically,
cases of B. canis have been documented in the United States (particularly the southern
states), Mexico, Canada, Central and South America, some European countries, Tunisia,
Nigeria, Madagascar, Malaysia, India, Korea, Japan and China. Brucella canis, like B.
ovis, is a species of Brucella that has a naturally rough phenotype in its infectious form.
The primary host for B. canis is the canine, and both male and female animals are
affected. Transmission of the organism can be venereal or through contact of mucous
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membranes with urine or with infectious tissues following an abortion. Females have
been shown to shed the bacterium in vaginal discharges for up to 6 weeks following an
abortion. Males have been shown to shed the bacteria sporadically for years after initial
infection in semen and urine. Live B. canis can also be found in milk, urine, saliva, nasal
and ocular secretions, and feces of infected animals (Ledbetter et al. 2009, Wanke et al.
2004). Canine brucellosis is typically manifested as late-term abortions in females and
sterility in males. Seemingly healthy pups may be born congenitally infected and
develop symptoms later in life (Iowa 2009). In males, orchitis, epididymitis, scrotal
edema, and sterility have been observed. Other symptoms may include lymphadenitis,
fatigue, loss of appetite, loss of alertness, and behavioral abnormalities. Infected animals
often do not appear outwardly ill but can remain infected for up to 5 years (Wanke et al.
2004). Canine brucellosis is rarely fatal. Antibiotic treatment is available, although
some forms of treatment are expensive while others are not always effectual. The
greatest economic impact of the disease is seen in breeding kennels, where up to 75%
fewer puppies have been noted in some affected kennels (Iowa 2009). There is no
vaccine available for B. canis, and control is most often performed by removal of infected
animals and sanitation of the kennel or living space previously occupied by the animal.
Human infection is rare and normally occurs in immunosuppressed individuals if
contact of the mucosal membrane or abraded skin occurs with >1×106 organisms.
Symptoms in people infected with B. canis are similar to those seen with other species of
zoonotic Brucella. Although it is a zoonotic pathogen, B. canis is not considered to be a
potential agent of bioterrorism.
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Brucella neotomae and Other Proposed Brucella Species of Terrestrial Animals
Brucella neotomae was first described in 1957 after isolation from the desert
wood rat in the United States by Stoenner and Lackman (Cameron and Meyer 1958).
Brucella neotomae is a smooth organism, has a distinctive metabolic pattern, and
performs similarly on biochemical tests used to identify other species of Brucella (Meyer
1990).
Most recently, B. microti has been described as a Brucella species isolated from
common voles in the Czech Republic and red foxes in lower Austria (Scholz et al. 2009).
Another proposed species of Brucella is the newly described B. inopinata, which was
isolated in Germany from a breast implant wound of a 71-year old woman. B. inopinata
is genetically highly homologous to other recognized Brucella strains but exhibits a
unique 16S gene sequence (Scholz et al. 2009). Studies on these new proposed strains
are ongoing. Further research is needed to determine their threat to agriculture or
economy.
Brucella ceti and Brucella pinnipedialis
Brucella ceti and B. pinnipedialis have been recently described as the cause of
brucellosis in marine mammals (Foster et al. 2007). In 1990, a common dolphin from the
English coast tested seropositive for anti-Brucella antibodies, sparking research into the
field of marine mammal brucellosis worldwide (Jepson et al. 1997). These two species
were placed in the Brucella genus because they are aerobic, non-motile and catalasepositive. Furthermore, these species have a greater than 77% homology to other species
in the genus Brucella (Foster et al. 2007). Brucella ceti is the name given to the novel
Brucella species causing brucellosis in cetaceans (such as whales, dolphins, and
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porpoises). Brucella pinnipedialis is the name given to the novel Brucella species
causing brucellosis in pinnipeds (such as seals, sea lions, and walruses). Brucella strains
have also been isolated from several marine mammals, including common seals,
porpoises, common dolphins, bottlenose dolphins, white sided dolphins, striped dolphins,
minke whales, Pacific harbour seals, ringed seals, harp seals, and European otters
(Forester et al. 2007). Symptoms vary from asymptomatic to observed cases of orchitis,
abortion, and meningeoenephalitis (MacDonald et al. 2006).
Human infection has also been reported in individuals working closely with
marine mammals (Brew et al. 1999). It is reported that brucellosis in humans from
marine mammals is similar to the disease contracted from terrestrial animals with
symptoms including headaches, malaise, severe sinusitis, seizures and spinal
osteomyelitis (MacDonald et al. 2006). As these species are a new area of research, more
studies must be performed to determine their ultimate threat to public health.
Human Brucellosis
Brucellosis in humans is a disease that has the potential to affect several systems
with symptoms ranging from mild to severe. Transmission is normally from infected
animals. Incubation periods may vary from weeks to several months before symptoms
fully develop (Franco et al. 2007). Infected individuals may experience undulating fever,
fatigue, and headaches, as well as joint and back pain. These symptoms may have longterm or chronic effects in some patients. More serious symptoms are observed in cases
where the bacterium has migrated to the central nervous system or endocardium, in which
case meningitis, endocarditis and psychoneurosis can occur (Franco et al. 2007, Alapin
1976, Harris et al. 1954). Although brucellosis is not typically considered a fatal disease,

18

human cases left untreated can result in mortality (Park et al. 2007, Franco et al. 2007). It
is believed that many cases of human brucellosis remain undiagnosed and thus
unreported. This may be due to the similarity of initial symptoms to those of influenza
(Chain et al. 2005).
Human brucellosis is diagnosed using serological testing and by culturing bacteria
from blood, lymph, or cerebrospinal fluid (Seleem 2009). Disadvantages of this method
include the slow growth of Brucella in culture and a potentially low number of colony
forming units (CFU) present in clinical samples due to the stage of infection or to the use
of antibiotics prior to sample collection (Seleem 2009, Franco et al. 2007). The Rose
Bengal test is also useful for human diagnosis, as well as specially designed ELISAs
(Acha et al. 2003, Orduna et al. 2000). The tube agglutination test was the first test used
for diagnosis of brucellosis in humans and was later adapted for use in animals. In this
test, sera is diluted and added to a tube containing a standard quantity of killed Brucella
cells. The occurrence of clearing and agglutination following incubation is considered a
positive result (Beran 1994). Wright’s serum agglutination test, which measures the titer
of anti-brucella antibodies (Mert et al. 2003), and Huddleson’s slide agglutination test, in
which serum agglutination can be rapidly detected (Spink 1956), are successful
diagnostic tools for brucellosis. Studies surrounding the use of molecular-based diagnosis
using the Polymerase Chain Reaction (PCR) have also been explored with varied results
(Kattar et al. 2007). It is also crucial to obtain a detailed case history of any travels to
endemic countries or ingestion of any untreated animal products imported from endemic
countries.
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Treatment for human brucellosis is most commonly through combined antibiotic
regimens, as treatments using single antibiotics have shown higher relapse rates (Pappas
et al. 2005 & 2006, Solera et al. 1997). The recommended combination is doxycycline
coupled with rifampin, but doxycycline with streptomycin or gentamicin have also been
effective treatments (Seleem 2009, Solera et al. 1997). Prior to 1986, the World Health
Organization (WHO) reported that a doxycycline-streptomycin regimen was the preferred
method of treatment for brucellosis in human adults. Currently, however, the WHO
Committee on Brucellosis has updated their recommendation to a combined oral
treatment of 600-900 mg of rifampicin daily coupled with 200mg/day of doxycycline for
a period of 6 weeks for the treatment of acute brucellosis in human adults (WHO 2004).
Regardless of therapeutic regimen used, relapse rates of approximately 5-10% have been
observed in both adults and children treated for brucellosis (Hall 1990).
Caprine Model for Brucellosis
The goat serves as the primary host for B. melitensis, which is the most
pathogenic species in humans, and as a secondary host for B. abortus, which produces
clinical symptoms similar to those observed in cattle. Because both species pose a threat
to public health and agriculture, the development of new and more efficient vaccines are
an important area of research. There is no single vaccine effective against both species
that is safe to use at any stage of gestation (Elzer et al. 2002). Some commonly used
vaccines, such as S19 and Rev.1, conflict with serological diagnosis, becoming an
obstacle for efforts to eradicate the disease. The development of a caprine model for the
study of improved vaccine candidates and other genetic mutants was proposed by Elzer et
al.. in 2002.
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The use of the caprine model was a logical choice for the study of modified
Brucella strains. As compared to the commonly used murine model, the goat is a natural
ruminant host (Elzer 2002). The goat model is also advantageous over the bovine model
due to its lower cost and decreased gestation periods. Furthermore, these attributes allow
larger cohort sizes for increased statistical significance (Elzer et al. 2002). The model
focuses first on bacterial colonization, monitoring of both pregnant and non-pregnant
female animals, as well as the fetus and kid, following conjuctival administration. The
colonization assay is performed using various tissue samples obtained at necropsy for
bacteriological and serological analysis (Elzer et al. 2002). In this way, the propagation
of the pathogen throughout the animal can be monitored. A pathogenicity assay was
developed to study the colonization capability of experimental mutants on the dam and
subsequently the fetus (Elzer et al. 2002). To test vaccine efficacy, a third assay was
developed using non-pregnant females given an experimental vaccine followed by
impregnation and a challenge infection at approximately 110 days gestation with virulent
B. melitensis 16M and/or B. abortus 2308 (Elzer et al. 2002).
Brucella melitensis in the Caprine Host
B. melitensis infects the goat as its primary host and can be quickly transmitted
from infected dams via vaginal discharges, fetal fluids, placenta, and the fetus itself.
Goats are capable of shedding the bacterium for 2-3 months post-parturition in vaginal
discharges. There is also long-term shedding observed in milk (Iowa State University,
2009). The usual route of infection is through contact of any of these infectious tissues
with mucous membranes. The outcome of exposure varies dependant on the age and
health condition of the animal as well as the number of invading bacteria (Alton 1990).
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Once infected, animals may experience abortions in pregnant females and
impaired fertility in males. Non-pregnant animals are often asymptomatic (Iowa 2009).
It has been observed that abortions occur in 70-100% of infected pregnant females; and
of those, 90-100% of the dam/kid pairs are found to be culture positive (Elzer et al.
2002). Kids that are not aborted are normally weak at birth and found to be colonized
with B. melitensis. Elimination of the infection is most easily accomplished by slaughter
of the herd (Merck 2006, Alton 1990).
Brucella abortus in the Caprine Host
The primary hosts for B. abortus are cattle, but an infection in goats (a secondary
host) resembles bovine brucellosis in clinical symptoms and provides a model for the
study of B. abortus in cattle (Anderson et al. 1986, Meador et al. 1986 & 1989, Elzer
2002). Abortion and colonization are not as prevalent in caprine B. abortus infections
with an approximately 30-50% abortion rate in infected females and a 50-70%
colonization rate in dam/kid pairs (Elzer et al. 2002). It has been observed that both
nursing and non-nursing females shed the bacterium, but non-nursing females tend to
have higher concentrations of B. abortus in their milk (Meador et al. 1986). The
colostrum of infected animals tested positive for anti-brucella antibodies, which have
been shown to pass to previously antibody-negative neonatal kids following colostral
intake (Meador et al. 1986 & 1989).
The serological and clinical pattern observed in the caprine host due to B. abortus
infection is sufficient for the study of B. abortus-derived vaccines in the goat model.
Serologically, B. abortus RB51 does not revert from a rough to smooth phenotype in the
goat, does not promote the formation of anti-OPS antibodies that may interfere with
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diagnostic tests, and is capable of inducing the production of anti-Brucella antibodies to
rough antigens (Shurig et al. 1991, Roop et al. 1991). Clinically, RB51 does not induce
abortions in the caprine host when fetuses are injected during the final 50 days of
gestation (Roop et al. 1991). RB51 is cleared rapidly from the caprine and ovine host,
showing a marked reduction in virulence and survivability when compared to Rev.1 in
the these animals. Thus, commercial RB51 has been shown to provide inadequate
protection in the caprine and ovine hosts against B. melitensis challenge (Adone et al.
2005, Neilson et al. 2004).
Brucella Vaccines
Vaccination against bovine brucellosis, a disease caused by B. abortus, is a
powerful tool in the effort to eradicate the disease in the United States. The first
brucellosis vaccine approved for field use by the US government, smooth B. abortus
Strain 19 (S19), was approved and implemented in 1941 (Neilson et al. 1990). Conflicts
with S19 arose with diagnostic testing and a new rough vaccine, B. abortus RB51
(RB51), was approved by the USDA to replace S19 as the standard brucellosis vaccine in
1996 (USDA 1996). Although RB51 resolved the problems presented by S19 with
diagnostic testing, the popular opinion of RB51 is that it may be a less efficacious
vaccine than S19. The immunogenic differences between S19 and RB51 are principally a
manifestation of differences in structure, function, and survivability in the host.
The responses of the host’s immune system to a typical infective strain of B.
abortus include both cell-mediated and humoral reactions. The humoral reactions are
those involving the production and function of antibodies that target the surface
components of the cell’s outer membrane and complement. Studies on the role of
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complement have shown it to be ineffective in combating B. abortus directly, but it may
aid in phagocytosis (Timoney et al. 1998)( Barquero-Calvo et al. 1997). The primary
immunogenic component of the smooth outer membrane is the O-polysaccharide (OPS)
component of the lipopolysaccharide (LPS). The antibody response to the OPS mediated
by the host is ineffective in providing protective immunity against a challenge infection
as shown through effectiveness of the rough RB51 vaccine strain. In fact, the presence of
IgG1 antibodies predominantly produced in response to B. abortus does not correlate to
elimination of the pathogen (Bellaire et al. 2005). However, opsonic antibodies can
promote intracellular killing and slow the reproduction rate of intracellular B. abortus,
but antibodies alone are not effective in clearing the pathogen from the host (Timoney et
al. 1998, Arenas et al. 2000, Bellaire et al. 2005). In terms of vaccination, the cellmediated immune response is primarily responsible for protective immunity.
The cell-mediated immune response to B. abortus is primarily mediated by
activation of phagocytes and T-cells of the adaptive immune response. The role of cellmediated immunity is to identify and destroy host cells housing harmful intracellular
pathogens, such as viruses and facultative or obligate intracellular bacteria (Abbas 2005).
For B. abortus, the macrophage is primarily responsible for ingestion and clearance of the
pathogen from the extracellular environment. Macrophages that are not activated prior to
ingestion of B. abortus differ in their interaction with the pathogen than do previously
activated macrophages, which are considerably more brucellacidal (Barquero-Calvo et al.
2007, Elzer 2007). Antigen presentation to both CD4 and CD8 T-cells is a key
occurrence in the host’s development of protective immunity. B. abortus ingested by
inactivated macrophages can inhibit development of the phagolysosome or neutralize the
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acidic environment therein, avoid killing, and eventually replicate within the cell
relatively undetected (Barquero-Calvo et al. 2007). In these inactivated phagocytes, the
pathogen causes the macrophages to become immunosuppressive against a strong CD4+
Th1 response (Forestier et al. 2000). However, previously activated , or immune,
macrophages degrade B. abortus upon ingestion and phagolysosomal fusion, where it can
be recognized and presented to CD4+ Th1 cells by the MHCII receptor. An effector
CD4+ Th1 cell further activates macrophages by secreting IFNγ, which triggers an
increase in antimicrobial activities against the pathogen. Likewise, B.abortus elicits a
strong CD8+ T cell response, which mediates cytotoxic activity and functions to lyse
infected cells. If a macrophage that houses replicating B. abortus cells is lysed, the
pathogen is released into the extracellular environment, where it can either infect other
cells or become ingested and destroyed by activated macrophages (Elzer 2007, Baldwin
and Winter 1994, Jones 1992, Araya et al. 1989).
Brucella abortus S19
The S19 vaccine strain was developed in 1923 by Dr. John Buck and was shown
to produce adequate immunogenicity in guinea pigs without causing detrimental
pathology. Dr. Buck found that S19 was similarly effective in cows against challenge
infections when given in the correct dose. Statistically, S19 provides 70-90% protection
in pregnant heifers in preventing abortion and infection (Nicoletti 1990). This attenuated
strain was created by isolating a virulent B. abortus strain from an infected animal which
was then serially-passaged and allowed to incubate at room temperature for several
months. When examined, Dr. Buck found the isolate to be attenuated (Graves 1943).
However, it has also been observed that S19 may cause abortions in pregnant cows,
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orchitis in bulls, pyrexia, and other infections in some cases (Nicoletti 1990). Human
infections have also been reported through accidental vaccination or exposure (Wallach
et al. 2008). Antibodies to S19 can be passed from cow to calf through the colostrum
following birth. If calves are vaccinated during this period, these maternal antibodies are
capable of neutralizing or killing S19. Vaccination of cattle herds is typically performed
in 3 to 6 month old heifers at a standard dose of 5×1010 to 8×1010 CFU (OIE 2009,
Poester et al. 2006).
The immunologic response to S19 is similar to that of an infectious strain of B.
abortus, but does not result in a full infection (Nielson et al. 1990). S19 is a smooth
strain of B. abortus and expresses a fully intact and functional LPS with the OPS on the
surface of the outer membrane. Because the OPS is a primary immunoantigen, S19 is
capable of inducing the production of OPS-specific antibodies in the host, stimulating
both cell-mediated and humoral immunity. However, this feature of S19 is problematic
since standard diagnostic tests detect the presence of anti-OPS immunoglobins as a falsepositive reaction. Typically, S19 will provide protection against virulent B. abortus for
several years while the presence of anti-OPS antibodies will decrease within months of
vaccination. However, it has been observed that some animals become infected
permanently with S19 following vaccination, continuing to produce anti-OPS antibodies
for years following vaccination (Jacob et al. 2005). For these chronic shedders, serologic
tests will constantly provide positive results for vaccinated animals that are uninfected.
Because of this issue, a new vaccine, named RB51, was licensed in 1996 that was
a rough strain of B. abortus 2308 (USDA 1996). Because RB51 lacks the OPS found on
virulent strains of B. abortus as well as on the S19 vaccine strain, the problem with
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diagnostic tests was solved. RB51 does not promote the production of anti-OPS
antibodies in a strong humoral response, yet is effective in providing adequate protection
against challenge infections (Poester et al. 2006).
B. abortus RB51
The current U.S. vaccine used to protect cattle against bovine brucellosis is the B.
abortus RB51 vaccine strain. RB51 was developed by making serial-passages of B.
abortus 2308 on rifampicin and penicillin supplemented Tryptic soy agar (TSA) plates
(Schurig et al. 1991). The resultant RB51 strain was rifampicin-resistant and lacked the
OPS of the original smooth 2308 strain. Genetically, this is due to a defect in the LPS
biosynthesis loci (Vemulapalli et al. 2004). Although there was concern surrounding the
release of an antibiotic-resistant strain of B. abortus, in February of 1996 the United
States designated RB51 as the premier vaccine, replacing the Strain 19 vaccine used prior
to this switch (Poester et al. 2006).
RB51, which lacks the O-polysaccharide chain normally found on strain 19 and
wild-type Brucella abortus, does not initiate the production of smooth OPS antibodies in
the vaccinated animal. Thus, RB51, unlike strain 19, does not produce a positive test
result for an animal that is negative for brucellosis but has been exposed to B. abortus
through vaccination. It has also been shown that RB51 does not revert to a smooth
phenotype when administered. RB51 has also been shown to be equally efficacious as
strain 19, but is less abortigenic and does not produce any symptoms of disease after
vaccination (Poester et al. 2006) (Perry 2005). RB51 does not produce a very strong
antibody reaction in the vaccinated animal but it does cause a cell-mediated response that
is the primary factor in protecting the animal from a full infection (Poester et al. 2006).

27

Studies have shown that RB51 is 70-90% effective in preventing abortions and disease in
cattle tested (Stevens et al. 1995) (USDA 1996). Currently, RB51 remains the principal
vaccine for bovine brucellosis at this time and an important component of the StateFederal Brucellosis Eradication Program. Domestic calves are vaccinated with RB51 at 4
to 12 months of age at a dosage of 1.0-3.4x1010 CFU and tagged appropriately (USDA
1996, Poester et al. 2006). Following vaccination, RB51 is quickly cleared from the
draining lymph nodes (Chevelle et al. 1992 & 1993). Over the course of a typical
vaccination with live attenuated RB51, the organism is typically cleared from cattle in 6
to 8 weeks. RB51 is usually undetectable in the blood stream within a period of 3 days
and are not present in mucosal secretions (USDA 1996). Both subcutaneous and
conjunctival administrations of RB51 have been proven effective in conferring protection
against challenge infections of B. abortus (Jiménez de Bagüés et al. 1994, Stevens et al.
1996), and experiments focused on oral vaccination have yielded promising results (Elzer
et al. 1998).
Brucella melitensis Rev.1
The Rev.1 vaccine was developed in 1957 by Elberg and Herzberg for the
protection of goats and sheep against B. melitensis and is a streptomycin-non-dependent
reverse mutant of the streptomycin-dependent B. melitensis 5056, a virulent strain
(Sanmartino 2005). Low virulence has been observed in small ruminants when the
vaccine is administered under standard conditions. Furthermore, upon continued
passage, Rev. 1 does not revert to a pathogenic form (Diaz-Aparicio 2004). Similarly to
S19, Rev-1 is a smooth strain with an intact OPS. Thus, Rev.1 vaccinated animals
produce antibodies identical to animals naturally infected with wild-type Brucella, which
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may produce false positive results using standard serological tests.
When administered to pregnant animals, Rev.1 has been shown to be abortigenic
at standard vaccination doses. It is also found that a reduced dosage of Rev.1 does not
fully prevent the induction of abortion and does not confer full protection against B.
melitensis infections in both goats and sheep (Gonzalez et al. 2008, Blasco 1997).
Because of the pathogenicity issues when administered to pregnant animals, there is no
completely safe strategy for vaccination using Rev.1. Conjunctival vaccination of sheep
during lambing season or late lactation has been suggested as an optimal vaccination
strategy for adequate protection with a reduced frequency of abortion (Blasco 1997).
The recommended vaccination method for Rev.1 is to use a standard dose (1x109
to 2x109 CFU) subcutaneously injected for female goats and sheep at the age of 4 to 6
months old. Following vaccination, Rev.1 causes infection in the animal for a period of 3
months, with colonization generally restricted to the lymph nodes and spleen. The
organism has also been located intracellularly in the dendritic follicular cells and
macrophages of the draining lymph nodes following vaccination (Munoz 2008). Strain
persistence has also been reported due to horizontal spread among vaccinated herds
(Banai 2002, Bardenstein et al. 2002). Rev.1 induces a potent antibody response, which
poses an obstacle to diagnostic serological tests (Blasco 2006). Reduced serological
responses have been observed in animals administered Rev.1 through conjunctival
vaccination, as opposed to subcutaneous injection.
Other Vaccine Research
In attempts to increase the safety of vaccination, studies to develop a vaccine that
is protective and non-pathogenic in animals, as well as non-infectious to humans were
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conducted. Vaccines produced from killed field isolates and laboratory strains have met
with mixed reviews. Although some vaccine candidates decreased pathogenicity,
protection provided was inadequate (Schurig 2002). Furthermore, in killed vaccines
using smooth strains of Brucella, positive serology poses a problem to detection
capabilities using standard diagnostic tests. Vaccines developed using antigenic fractions
of Brucella cells, including portions of the Brucella cellular envelope, outer membrane
proteins, and LPS fractions, among other proteins, have been tested. Some vaccines
utilizing antigenic fractions, when administered using an immunogenic adjuvant, have
provided immunity in laboratory tests (Shurig 2002). DNA vaccine research for
brucellosis is limited to small laboratory animals and has not been examined for use in
natural hosts. In these studies, the level of protection provided by DNA vaccines is
inferior when compared to the live-attenuated vaccines currently in use (Schurig 2002).
Nevertheless, there is no killed or sub-unit Brucella vaccine approved for commercial
use.
Human vaccine trials
There is no vaccine against any species of Brucella that is safe for human use.
The vaccines previously described for use in animals are infectious to humans, and some
carry antibiotic resistance genes that are a cause of concern when considering treatment
methods. In developing countries in which brucellosis is rampant, human vaccine trials
have been performed with little success. Attenuated live vaccine strains administered to
humans show varied protective capabilities and adverse side-effects. Human vaccine
trials using sub-unit brucellosis vaccines also provide varied results (Schurig 2002). The
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development of a vaccine for human use in countries where the disease has been
eradicated is also of interest considering the status of brucellosis as a bioterrorist threat.
It is generally accepted, however, that the best prevention technique for brucellosis in
humans is through eradication of the disease in animals and proper treatment of food
products intended for human consumption.
Brucella Genomic Studies
There are currently ten fully sequenced Brucella strain genomes available from
five species of Brucellae (B. abortus, B. melitensis, B. suis, B. ovis, and B. canis).
Twenty five additional Brucellae genomes are also in the progress of being sequenced
(Seleem et al. 2009). Complete genomic sequences allow researchers the opportunity to
study and manipulate genes of Brucella spp. and their protein products in order to learn
more about the functional aspects of virulence, replication, and survival of this organism,
both in and out of the host. Not only does this provide insight into the genetic coding
sequences unique to brucellae, but it also facilitates the studies of conserved coding
sequences and their comparative functions across several species of bacterial pathogens.
Genomic studies have also facilitated proteomic studies to identify proteins involved in
virulence, pathogenicity, and host specificity. Expanding genomic data has provided new
perspectives into the examination of the Brucella genus as a whole, as well as
comparative studies between Brucella species. Manipulation of the Brucella genome has
permitted the determination of the function of several genes. Genes involved in host
specificity, survival, and virulence are frequently targeted in efforts to improve
vaccination. Techniques such as genetic transformation or gene disruption in Brucella
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spp. are widely used to study specific genes with successful results (Zygmunt et al.
2006).
Molecular transformation is a method in which the natural characteristics of an
organism can be manipulated by altering its genetic repertoire. This technique has been
used frequently in the study of genetic complementation in brucellae. Methodology
includes the construction of a plasmid vector containing a selective marker and the gene
region of interest, transformation of the vector into the cell, and selection of genetically
modified cells. The pBBR1MCS plasmid is a broad-host-range vector that is stably
maintained in Brucella species, under both in vivo and in vitro conditions (Elzer et al.
1995). The vector is retained at a low copy number within the cell, but is not integrated
into the genome (Kovach et al. 1995, Elzer et al. 1995). Variations of the pBBR1MCS
plasmid contain different selectable markers used for the identification of effectively
modified organisms.
Other methods frequently used in genetic manipulation include Gateway-based
destination vectors and gene disruption or deletion. The Gateway recombination cloning
system is used to move genes into a multiple vector system for functional analysis and
protein expression without the use of the restriction endonucleases and ligases used in
traditional cloning methods (Invitrogen 2003). This system has been used to identify and
study open reading frames of B. melitensis and B. abortus at a proteomic level to
determine biological function (Dricot et al. 2004, Hallez et al. 2007).
Suicide vectors, also known as gene-replacement plasmids, are utilized for sitedirected chromosomal insertion by homologous recombination between homologous
DNA sequences. The vector itself does not replicate and is not maintained in the cell
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(Elzer et al. 1995). Gene-replacement plasmids are introduced via electroporation or
chemical treatment into the cell, similar to the methodology described previously. The
goal is to replace a target gene of interest within the genome with a gene from the vector,
most often carrying a selectable marker for the detection of modified cells (Sherratt
1995). The marker present on the vector is flanked with sequences homologous to those
flanking the wildtype gene of interest within the genome. After introduction into the cell,
the wildtype gene of interest is disrupted, following a double-crossover homologous
recombination event which incorporates the selectable marker into the genome (Sherratt
1995). This method is a form of site-directed mutagenesis.
Another method of gene disruption is through transposon mutagenesis. This
technique uses random gene inactivation to identify cellular functions associated with
virulence and survival (Wu et al. 2006). This form of mutagenesis allows the random
transference of genes, most often selectable markers, into the chromosome of a host
organism using transposable elements, potentially disrupting the wildtype gene located at
the insertion site. A pool is created from those mutants selected to have taken up the
selective gene carried by the transposon. This mutant pool is then introduced into a host
animal and analyzed for reductions in virulence as compared to the wildtype strain. This
method of mutagenesis is randomized and not directed to specific genes.
Gene disruption or deletion mutants obtained using the methods above are
analyzed in vivo with regard to reduced survival and intracellular replication to determine
the function of the particular gene in question. Studies in Brucella species using gene
disruption or deletion mutants have proven successful in examining specific genes of
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interest (Halling et al. 1991, Tatum et al. 1993, Drazek et al. 1995, Edmonds et al. 2001
& 2002, Wu et al. 2006).
Hemagglutinins
Blood agglutinins are produced by many pathogens, including bacteria, viruses,
parasites, and plants (Nelson et al. 2006). Much of the current research performed on
pathologic hemagglutination is focused on viral hemagglutinins, namely the influenza
virus. There are two primary functions of viral hemagglutinins in infection: to recognize
the host cell via sialic acid-associated receptors and to facilitate entry of the viral genome
into the target host cell (Gambrian et al. 2006, Suzuki 2005, White et al. 1997).
In historical studies conducted under in vitro conditions, it was discovered that
some bacteria produce proteins that promote the agglutination of red blood cells (Netter
et al. 1954). The bacterial hemagglutinin has been proposed to function in adherence of
the organism to the surface of host cells (Alam et al. 1997). Direct bacterial
hemagglutination occurs when the protein hemagglutinin itself causes the agglutination
of erythrocytes (Neter et al. 1954). This was first described by Kraus and Ludwig in
1902 (Koransky et al. 1975). Indirect hemagglutination occurs when the bacteria
increase the liability of the RBC to agglutination by antibodies by bringing about a
physiological change in the surface properties of the erythrocyte (Neter et al. 1965).
Although many proteins have been studied as hemagglutinins, the
lipopolysaccharide (LPS) has been the focus of many bacterial hemagglutination
experiments (Alam et al. 1997, Watkins et al. 1987). The LPS of Brucella species serves
several functions in virulence and survival of the pathogen, yet rough strains are also
capable of virulence and survival in vivo. Furthermore, there is no data that shows the
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Brucella LPS as being involved in invasion of the host cell (Rocha et al. 1999, Aragon et
al. 1996). However, there is data that shows an increased rate of adherence and uptake
into host cells for rough strains of Brucella as compared to smooth strains, yet rough
strains were not as efficient to replicate within the host cells (Ferrero et al. 2009). This
suggests an adherence mechanism separate from the LPS. The mechanisms concerning
the association of Brucella to host epithelial cells, RBCs or the effector molecules
involved in cellular uptake are not clearly understood. Since cellular adherence is
necessary for uptake of facultative intracellular pathogens, it is important to understand
the mechanisms and molecules involved in this process. Many studies have been
performed to identify and characterize virulence factors produced by Brucella species
that are associated with the attachment and invasion of host cells, yet exact mechanisms
remain unclear (Rosetti et al. 2009, Ferrero et al. 2009, Castaneda-Roldan et al. 2006 &
2004, Rocha et al. 2002 & 1999, Guzman-Verri et al. 2001, Zaitseva et al. 1996, Eskra et
al. 1991, Hoffman et al. 1990, Vendrell et al. 1990).
An increase in the identification and study of virulence genes for Brucella species
has occurred since the mapping of several Brucella genomes. In 2002, DelVecchio et al.
described a gene coding for a putative hemagglutinin (GI:17989062) found in the
genomic sequences of B. melitensis and B. ovis (DelVecchio et al. 2002a &2002b). A
highly homologous but not identical gene sequence is also found in B. suis and B. canis.
Other matches with some homology to the B. melitensis putative hemagglutinin gene are
as follows: a B. ovis hemagglutinin (GI:148558421); a B. melitensis glycoprotein X
precursor (GI:225686341); a cell wall protein AWA1 precursor in B. suis
(GI:254702929), B. canis (GI:161620616), B. ceti (GI:254715437), and B. pinnipedialis
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(GI:254708522); and a putative cell wall surface protein of B. ovis (GI:148558357) and
B. suis (GI:23500299). The gene is not naturally found in any strain or subspecies of B.
abortus.
Previous studies were performed on suspected Brucella hemagglutinins and their
agglutinative properties on human and animal erythrocytes. It was shown that B. abortus
2308 has a significantly lower titer using the hemagglutination test, as described by
Evans et al. (1980), than B. melitensis 16M. Furthermore, the previously described B.
melitensis hemagglutinin (GI:17989062) was investigated in the caprine model. The
gene was placed into B. abortus 2308 via the pBBR1MCS-4 plasmid (tagged 2308-QAE)
and a gene deletion B. melitensis 16M mutant was also created. The B. abortus 2308QAE strain showed increased virulence (as compared to B. abortus wild-type) in
colonization and pathogenicity studies, similar to the results in the B. melitensis 16M
challenge animals. The 16M deletion mutant showed no signs of attenuation in
colonization of a caprine host, but the pregnant animals that received the deletion mutant
showed a 30% reduction in abortions when compared to the parent B. melitensis strain. It
was concluded that the specific QAE gene was a putative hemagglutinin and virulence
factor of B. melitensis, as well as a possible host specificity factor for the caprine host
(Perry 2007).
Protein Characterization
Identification of protein characteristics is an integral part of learning the
functional aspects of a protein as well as the role it plays in cellular activity and survival
as a whole. Protein expression and function may vary depending on in vivo or in vitro
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conditions, making it necessary to examine both avenues in characterization of the same
protein.
For assessment of protein expression in vivo, cellular activity inside of a living
animal host is examined. The identification of protein-specific antibodies using western
immunoblot techniques and absorption assays are useful in determining the relative size
and antigenicity of a specific protein. Antibody absorption assays examine immune sera
by combinination with lysates of the in vitro-grown pathogen to identify antibodies
specific for proteins exclusive to expression in vivo by removal of cross-reacting
antibodies (Handfield et al. 2000). Specifically, the serum of an animal that has been
exposed to a protein of interest via infection or vaccination and, in theory, contains in
vivo-produced, protein-specific antibodies is mixed with lysates from cells lacking the
gene for the protein of interest, but otherwise identical to the in vivo strain. This step
serves to remove any cross-reacting antibodies in the serum (Handfield et al. 2000,
Rollins et al. 2005). Next, the absorbed serum can be subjected to analysis by western
immunoblot containing cellular lysates of both the in vivo strain and the strain used for
absorption. Following identification by secondary antibody conjugation and blot
development, coupling of in vivo- produced antibodies to the protein of interest can be
analyzed to gain further information on the specific protein. This type of antibody
absorption assay is useful if the in vivo expressed protein of interest is sufficiently
antigenic to induce the production of antibodies adequate for detection using western
immunoblot (Handfield et al. 2000, Rollins et al. 2005). Specifically, this assay is most
useful in the examination of externally exposed or secreted proteins.
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For examination of proteins in vitro, cells are grown outside of an animal host in
or on laboratory-made media. There are numerous tests available to examine proteins
produced under in vitro conditions. Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and 2D gel electrophoresis followed by mass spectrometry
analysis are commonly used for the characterization of such proteins.
SDS-PAGE is a commonly used biochemical technique used to separate proteins
based on molecular weight. Proteins are separated on a polyacrylamide gel via
electrophoresis, during which an electric current is applied to the gel, causing negatively
charged proteins to migrate at different rates depending on the size of each protein
(Shapiro et al. 1967). Following protein separation via electrophoresis, the gel is stained
for visualization of the separated proteins. A common stain, Coomassie brilliant blue, is
commonly used due to its exceptional sensitivity to protein binding (Merril 1990). Once
stained, the separated proteins can then be examined based on molecular weight.
Analysis using 2D gel electrophoresis is a technique that separates proteins on
two dimensions: molecular weight and isoelectric point. This technique provides a
greater degree of protein separation than SDS-PAGE. 2D gel electrophoresis is also
considered to be the most sensitive procedure for the analysis of low abundance proteins
(Berth et al. 2007). This technique is commonly used to identify unique proteins between
two strains of highly homologous organisms. To achieve this, lysates from each strain
are subjected to 2D gel electrophoresis and examined, following staining, to locate any
unique proteins not shared by both strains. Further characterization of these unique
proteins can be assessed by mass spectrometry analysis, during which proteins are
ionized and introduced to a mass analyzer (Hernandez et al. 2006, Zhang et al. 1994).
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Proteins can be identified based on amino acid sequence and protein quantity can be
assessed.
Polymerase Chain Reaction
The Polymerase Chain Reaction (PCR) is a method used to amplify specific
regions of DNA from a large amount of diverse sequence for the purpose of visualization
and identification. PCR is widely applied in many different fields of science including
biochemistry, molecular biology, genetics, medicine and forensics. Because of the
sensitive nature of PCR, the workspace and technique must be both sterile and precise for
the prevention of contamination. However, there are several inhibiting factors for PCR in
even the most sterile conditions. PCR is currently being studied as a possible detection
method for brucellae in bodily fluids such as blood and urine (Navarro et al. 2006,
Queipo-Ortuno et al. 2006, Zerva et al. 2001, Morata et al. 1999, Yagupsky 1999).
Currently, there is no accepted standard for detection of brucellae using PCR and
detection is most often accomplished using tissue and blood cultures.
The current method of diagnosing brucellosis involves culturing the organism
from the blood, bone marrow or tissues or testing the animal for the presence of anti-OPS
antibodies (Yagupsky 1999). A standing problem with culture, most often from the
blood, is that Brucella are very slow growing organisms and several days are needed for
a positive confirmation, which can delay treatment. Standard diagnostic testing using
antibody recognition is also problematic due to false positives caused by Y. enterocolitica
0:9 infections and smooth vaccine strains. In endemic countries where brucellosis is a
serious threat to public health, the development of a more rapid yet still reliable method
for diagnosis would greatly detection and treatment methods. A PCR technique for the
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detection of Brucella species has many advantages over current methods. The PCR
technique itself is fairly easy to perform, affordable, and data can be acquired in less than
one day. Other advantages include the targeting of brucella-specific DNA and the
independence of antibody-based testing, which largely reduce the potential for crossreaction-based false positive results.
Currently, there is no standardized method for diagnosis of brucellosis using PCR
and detection capabilities have varied between labs (Elfaki et al. 2005, Navarro et al.
2004, Bricker 2002). Some studies have shown that diagnosis using PCR techniques
have had equal or better detection capabilities as blood culture, yet provided results in
only hours, as compared to days for culture (Navarro et al. 2006, Queipo-Ortuno et al.
2006, 2005 & 1997, Zerva et al. 2001, Morata et al. 1999). Conversely, there have also
been studies in which PCR techniques have provided inferior detection capabilities in
comparison with culture techniques (Maas et al. 2007, Kattar et al. 2007, Navarro et al.
2004 & 1999). Reasons for inconsistent results may lie in inconsistencies involving
techniques used among labs and in the variability of fluids tested. Many labs perform
PCR tests using whole blood cultures, however the heme-components found in whole
blood can inhibit PCR amplification. To circumvent this issue studies using serum were
evaluated, but were ineffectual in some cases if the patient tested was not bacteremic at
the time the sample was taken. Urine has also been tested, yet only two Brucella species
are shed in urine and neither is a threat to human health. Other inconsistencies were
found in the extraction of DNA using either manual DNA preparation versus the use of
different commercially available kits, periodic testing versus one-shot testing, and
differences in primers used. The most commonly used primer in PCR detection studies
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was developed by Baily et al. in 1992 for the detection of B. melitensis and B. abortus
(Baily et al. 1992). While successful trials have been reported in the use of the Baily
primers, other primers are also of interest in PCR techniques for Brucella detection. Of
note are the AMOS primers developed by Bricker et al., which are capable of
differentiating strains of B. abortus, B. melitensis, B. ovis, and B. suis by conventional
PCR and gel electrophoresis (Bricker et al. 1994). Studies using the AMOS primers have
provided promising results (Bricker et al. 2003, 1995). In some cases, the inability to
reproduce previously successful PCR techniques by other labs has been noted (Navarro et
al. 1999).
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HYPOTHESIS
The hypothesis for this study is that region E putative protein is a cell-surface
hemagglutinin and host specificity factor that, when expressed in trans through B.
abortus RB51 strain pQAE (RB51-QAE), will promote transient colonization of the host
and elicit an immune response greater than the parental RB51 without producing any
signs of adverse pathology of in the goat model. The modified strain of B. abortus
RB51-QAE was analyzed using an in vivo colonization study in the goat model and in
vitro experiments focused on hemagglutination, immunogenicity, and protein
characterization.
A second hypothesis for this study proposes that conventional PCR methods are
sufficient for the detection of both B. melitensis and B. abortus colony forming units in
whole blood, plasma, serum, and urine.

This hypothesis was tested using uninfected

whole blood, plasma, serum, and urine to create and test serial dilutions of B. melitensis
16M and B. abortus 2308 using the Omp25 and Baily primer sets, designed for the
detection of all Brucella spp.
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CHAPTER ONE
COMPARISON OF BRUCELLA ABORTUS RB51 AND RB51
CONTAINING PQAE IN THE CAPRINE MODEL
Introduction
Vaccination against brucellosis is an integral tool in efforts to control the disease
worldwide. The current vaccine used to protect cattle against bovine brucellosis is B.
abortus RB51, which lacks the OPS and does not interfere with serological testing
(USDA 1996). As a rough vaccine, RB51 does not produce a very strong antibody
reaction in the vaccinated animal; but it does induce a cell-mediated response for
protective immunity. RB51 provides limited protection in goats and little to no
protection in other animals, such as elk and bison, which serve as major U.S. reservoirs
for B. abortus in the wild (Moriyon et al. 2004). The Rev.1 vaccine has proven more
effective in the caprine host, but promotes antibody formation that interferes with
diagnostic testing. Development of an improved vaccine that is safe, effective, and does
not impede standard diagnostic testing could serve as an important advancement in
eradicating the disease globally.
Plasmid QAE (pQAE) was created to study a putative hemagglutinin found in B.
melitensis. The QAE plasmid consists of the pBBR1MCS-4 plasmid (which contains an
ampicillin resistance marker) and a region (designated region E, GI:17989062) from the
genome of B. melitensis that is hypothesized to contribute to virulence or host specificity.
The development of pQAE was accomplished by comparing the genomes of B. abortus
2308 and B. melitensis and finding gene regions that differed. Once a unique region was
found in the genome of B. melitensis, this region was investigated, isolated, and cloned
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into pBBR1MCS, and then electroporated into B. abortus 2308 (Perry 2007). This new
strain of 2308 (2308-QAE) was then used to infect pregnant goats. The results of this
experiment yielded approximately the same results seen for goats infected with B.
melitensis, indicating that the region of the B. melitensis genome that was carried by
pQAE and transferred to 2308 was effective in increasing host specificity (Perry 2007).
In addition, the effects of pQAE expression by B. abortus RB51 in the caprine
host were examined. Animals were conjunctivally inoculated with either RB51 or RB51
expressing pQAE (RB51-QAE) and tissue colonization levels were monitored over a
period of 42 days post-inoculation. It was expected that RB51-QAE would remain
attenuated, but survive longer in the tissues, potentially producing a greater immune
response and thus, a more broadly efficacious vaccine.
Successful trials with RB51-QAE may ultimately lead to the development of a
new, more effective vaccine that will serve as a better tool in the eradication of
brucellosis than the currently used RB51 vaccine. Due to the worldwide problem with
this pathogen and the need for an alternative vaccine, a caprine brucellosis model system
was developed for testing promising vaccine candidates (Elzer 2002). Using this
protocol, a vaccine candidate that incorporates pQAE into RB51 was tested. The goal of
this study was to compare the modified RB51 strain (RB51-QAE) with the parental strain
for colonization levels and pathological effects.

Materials and Methods
Creation of B. abortus RB51-QAE
A 100 μl dose of the B. abortus RB51 (Colorado Serum) parental strain was
plated on a brucella selective, blood agar (BS-BA) plate and incubated at 37°C in a 5%
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CO2 atmosphere for approximately 72 hours. All resultant colonies were harvested and
used to inoculate 25 ml of sterile Brucella broth. The cells were incubated overnight in a
shaking water bath set at 37°C.
The culture was then equally divided by placing 1 ml of the total culture into each
of twenty-five 1.5 ml microcentrifuge tubes. These cells were pelleted, the supernatant
discarded, and the pellets were combined into a single microcentrifuge tube. The pellet
was washed a total of 5 times in sterile dH2O then re-suspended in 100 μl of cold, sterile
dH2O.
For electroporation, 33 µl of the suspended RB51 cells were combined with 3 µl
of cold pQAE plasmid solution in an Eppendorf Electroporation Cuvette. The cuvette
was then placed in an Eppendorf 2510 Electroporator set at 2.5kV and was electroporated
for 5.6 ms. Immediately after electroporation, the cells were supplemented with 500 µl
of cold, sterile SOC-B recovery media. The cells were then left overnight in a shaking
water bath set at 37°C.
The next morning, BA plates containing 100 µg/ ml ampicillin were used to
spread 100 µl of the electroporated RB51-QAE cells. These plates were incubated for a
period of 2 weeks in a 37ºC, 5% CO2 environment and observed for growth daily after
the initial 72 hours.
All of the colonies growing after this 2 week period were suspected to be RB51QAE colonies and were tested accordingly. All resultant colonies tested positive for
oxidase, catalase, and urease tests, which is typical for B. abortus colonies. Furthermore,
a miniprep plasmid isolation was performed on rando mly selected colonies and the
pBBR1MCS-QAE plasmid was identified from these colonies. To detect the presence of
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region E in the isolated pQAE DNA, the cells were chloroform killed and a restriction
enzyme digestion using EcoR V (New England Biolabs) and PCR was performed, both
targeting the region E portion of pQAE. Samples of the pure pQAE plasmid, as well as
samples obtained through miniprep procedures following tissue culture, were sequenced
using BioMMED (Baton Rouge) facilities.
Confirmation of pQAE in B. abortus RB51-QAE
Plasmid isolation was performed using the Qiagen Buffer System kit (Qiagen,
Inc.) to verify the presence of pQAE in RB51-QAE cells. A broth culture of RB51-QAE
was allowed to incubate at 36°C overnight in a shaking water bath. Two ml of the
culture was pelleted by centrifuge at 9000rpm for 5 minutes and the supernatant was
separated then discarded. The pellet was then re-suspended in a series of three buffers;
300μl of Bufer P1 (50mM Tris base; 10mM EDTA, pH 8; 100 μg/ ml RNase A), then
300 μl of Buffer P2 (200mMNaOH, 1% SDS), and lastly 300 μl of chilled Buffer P3 (3.0
M CH3CO2K, pH 5.5). The tubes were vortexed after the addition of Buffer P1 and
mixed by inverting the tubes after the addition of Buffers P2 and P3. The tubes were
centrifuged at 14,000 rpm for 10 minutes, after which the supernatant was transferred to a
clean 1.5 ml microcentrifuge tube. The volume of the supernatant was measured and an
amount of isopropanol 0.7 times that of the total volume was added. The tubes were
inverted multiple times to precipitate the DNA and centrifuged for 15 minutes at 14,000
rpm. The supernatant was discarded, the DNA pellet was allowed to air dry, and was
then re-suspended in 25 μl of sterile dH2O.
Following plasmid DNA isolation, a Polymerase Chain Reaction (PCR)
amplification targeting the region E gene sequence was performed. The FailsafeTM PCR

46

System was used for this procedure, specifically with 2X Premix G (Epicentre
Biotechnologies). Twelve 2X Premixes (A-L), each containing a specific mix of dNTPs,
buffer, and varying amounts of MgCl2 and FailSafe™ PCR Enhancer (with betaine), were
subjected to a PCR assay with a control sample of region E DNA.
Reactions of 30μl were prepared for each of the pQAE isolation samples. For
each sample, 0.75 units of Failsafe PCR Enzyme Mix, containing a mix of thermostable
DNA polymerases, were added with 2X Premix G, 0.2μM of each primer, sterile dH2O,
and approximately 300 ng of template DNA. The primers used for this assay, ORF-944F
(5’-GAATTGGCGACCTGACTGAGGA- 3’) and ORF-944R (5’CTCACGGCTGTTCTCCTTTAACA- 3’), were designed to target the 1988 bp gene
sequence of region E. These primers were designed through The Institute of Molecular
Biology and Medicine at the University of Scranton (Scranton, PA) using the B.
melitensis 16M choromosome II gene sequence (Genbank Accession Number
AE008918). The primers were produced by Integrated DNA Technologies, Inc.
(Coralville, IA), re-suspended upon arrival using sterile dH2O, and stored at -20°C.
The PCR samples were placed in a MyCyclerTM Personal Thermal Cycler (BioRad
Laboratories, Inc., Hercules, CA). For the optimal amplification of Region E, an initial
denaturation step of 96°C was held for 5 minutes. Each reaction was then subjected to
denaturation at 96°C for 1 minute, annealing at 55°C for 30 seconds, and extension at
72°C for 2 minutes over 30 cycles. Lastly, a prolonged extension phase was programmed
for 5 minutes at 72°C. The amplified samples were stored at 4°C until visualization with
agarose gel electrophoresis using ethidium bromide staining.
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A restriction enzyme digestion was performed using EcoRV (New England
Biolabs) on the pQAE miniprep isolations purified from RB51-QAE. The purpose of this
procedure was to excise the region E gene sequence (approximately 2kb) from the pQAE
plasmid (approximately 4kb) for visual confirmation using agarose gel electrophoresis.
Twenty units of EcoRV were used with 2.5μl 100μg/ ml bovine serum albumin (BSA),
2.5μl of 1X NEBuffer3, and a volume of dH2O to bring the total volume to 25μl. The
reactions were incubated for 1 hour at 37°C in a shaking water bath under slight
agitation. To deactivate the restriction enzyme activity, the samples were placed in a
85°C heating block for 20 minutes.
Agarose gel electrophoresis was used to visualize the DNA products of PCR,
restriction enzyme digestion, and plasmid and genomic DNA isolation. A 5μl sample of
each DNA preparation was mixed with 5μl of 6X loading buffer (12% Ficoll 4000, 1.0 M
Na2EDTA, pH 8, 0.6% SDS. 0.15% bromphenol blue) and loaded onto a 1% agarose gel.
Molecular weight standards of either 100bp, 1 kb, or a supercoiled molecular weight
ladder (New England Biolabs) were run on each gel to determine the approximate size
and concentration of each DNA sample. The gel was made using UltraPureTM Agarose
(Invitrogen Corporation) in TAE buffer (Tris-base, Na2EDTA, glacial acetic acid). Each
gel was run in a BioRad DNA Sub Cell (BioRad Laboratories, Inc.) at 100V until the dye
front reached a distance of approximately 1 inch from the end of the gel. The gel was
stained in 1.0 μg/ ml ethidium bromide for 5-10 minutes, and then destained for 30
minutes to 1 hour in dH2O. The gels were next placed on a UV Transilluminator for
visualization. Documentation was performed using the PhotoDoc-It Imaging System
(UVP, LLC) to photograph each gel.
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Making of Infectious Doses
RB51-QAE colonies from the electroporation experiment that were proven to
contain pQAE were spread on three BA-AMP plates and incubated at 37ºC in a 5% CO2
atmosphere for approximately 72 hours. The cells were harvested from each plate using
2 ml of sterile broth per plate and the cells from all plates were combined in a single tube.
A tube containing 12 ml sterile broth was then inoculated with 50 µl of the harvested
cells and the optical density (OD) was determined (at 600nm). The desired absorbance
reading of 0.150 was obtained and is indicative of a 1x109 dilution. Using this
information, two tubes were prepared; the first with 6 ml broth and 2.5 ml culture for a
dilution of 1x1011, and the second with 24 ml broth and 100 µl culture for a dilution of
1x109. These dilutions were divided into 1 ml portions and placed in individual tubes,
which would serve as the infectious doses for this experiment. The tubes were flash
frozen and placed in a -80ºC freezer until needed. Plate counts were performed to ensure
the approximate cell count for one tube from each of the dilution groups. The results of
these plate counts confirmed an accurate CFU/ ml for each of the dilutions tested.
Animals
Twenty Brucella negative goats were divided into 2 groups of 10. Group 1 was
inoculated conjunctivally with commercially available RB51 vaccine (1x1010 colony
forming units), group 2 with the RB51-QAE vaccine (1x1010 colony forming units).
Blood samples were collected from each animal prior to inoculation and on the day of
necropsy. Initial blood samples were collected using Precision Glide Vacutainer Blood
Collection Needles (Becton Dickinson and Co.) in association with 10 ml BD red-top
Vacutainer Serum tubes (Becton Dickinson and Co.). The blood samples were allowed
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to clot overnight then centrifuged for separation. The serum was drawn off, subjected to
a Brucellosis card test, then stored for later use at -20°C. Blood collected at necropsy
was obtained through exsanguination.
From each of the groups, two goats were euthanized at 7, 14, 21, 28, and 42 days
post-vaccination using captive-bolt and exsanguination methods. Tissue samples
obtained at necropsy included the parotid lymph node, prescapular lymph node, liver
portions, spleen portions, internal iliac lymph node, and the supramammary and inguinal
lymph nodes of female and male goats, respectively. The individual tissues were
homogenized in 20 ml PBS, and 100μl were spread onto Brucella selective media (Oxoid
Ltd., Basingstoke, Hampshire, England) (Farrell 1974) then allowed incubate at 37°C for
a period of 2 weeks.
Bacteriological Examination
Resultant colonies were confirmed as Brucella or non-Brucella by the
morphological appearance of each colony and the activity of the colonies in question
when submitted to oxidase, catalase, and urease tests. Suspect RB51-QAE colonies were
also subjected to plasmid isolation and PCR targeting region E to ensure the presence of
region E in these cells. The confirmed Brucella colonies were counted and recorded in
the form of a growth chart comparing the time of sacrifice post-immunization and the log
CFU per organ for each of the vaccines tested.
A series of 10 biochemical tests were also performed to compare the results of B.
abortus 2308, RB51, and RB51-QAE. B. abortus 2308 was included because it is the
smooth parental strain of RB51. These tests included a Gram stain, serum agglutination,
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an acriflavin test, oxidase, catalase, urease, H2S, and TSI tests as well as dye sensitivity
tests with Thionin and Basic Fuchsin.
Serum agglutination was performed to determine a rough or smooth phenotype of
RB51 and RB51-QAE. This test was performed by placing a drop of commercially
available antisera against Brucella OPS (Fisher Scientifics) onto a clean glass slide and
mixing with it a suspect colony of RB51 from a Brucella Selective blood agar plate. The
same procedure was performed for suspect colonies of RB51-QAE. The results were
read based on the occurrence or absence of agglutination observed on the slide. Smooth
brucellae will cause agglutination, whereas rough brucellae will not.
Gram negative organisms with a rough phenotype will agglutinate when mixed
with acriflavin. This test was used as another method of determining the rough or smooth
characteristics of RB51 and RB51-QAE. For this test, a fresh solution of 10mg acriflavin
in 10 ml of sterile dH2O was made. A small volume of this solution was placed onto a
clean glass slide, then mixed into suspension with a colony of either RB51 or RB51-QAE
from an agar plate. The suspensions were observed for agglutination and the results
documented.
RB51 and RB51-QAE were also tested for the ability to produce cytochrome
oxidase, which reduces molecular oxygen, using the oxidase test. An oxidase reagent
ampule (Becton Dickenson and Co., Cockeysville, MD) was prepared by breaking the
ampule and mixing the contents within. Using a sterile cotton swab, a colony of either
RB51 or RB51-QAE was selected from an agar plate. The oxidase reagent was dropped
onto each swab and observed for 30 seconds. The results were read by the absence or
appearance of a violet color on the swab within 30 seconds.
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Catalase is an enzyme capable of converting hydrogen peroxide into oxygen and
H2O. To test for the presence of this enzyme in RB51 and RB51-QAE, a loop of each
organism was chosen from an agar plate and smeared onto a clean glass slide. One to
two drops of a commercial catalase reagent (Becton Dickenson and Co.) was added to
each slide and mixed with the suspect colonies of each strain. The test was read by the
formation or absence of oxygen bubbles forming within the mixture.
To test for the ability of RB51 and RB51-QAE to produce urease, which breaks
down urea into ammonia, CO2 and H2O, a urease test was performed. Urease slants
(Remel, Inc.) containing a pH indicator were streaked with an isolated colony of either
RB51 or RB51-QAE. The urease slants were incubated at 37°C in a 5% CO2 atmosphere
for 24 hours. The results were read by the presence or absence of a pink color produced
by the pH indicator, which will change colors in a basic environment.
A Hydrogen Sulfide (H2S) test was performed to test the ability of each strain
tested to produce H2S from amino acids containing sulfur. Triple sugar iron (TSI) media
(Remel, Inc.) was inoculated with either RB51 or RB51-QAE. A commercially available
lead acetate strip (Sigma-Fluka, Inc.) was secured between the cap and inner wall of the
media tube. The tubes were incubated overnight at a temperature of 37°C in a 5% CO2
atmosphere. The results were read by observing the development or absence of a black
color on the lead acetate strip. Using the same TSI media inoculated with either RB51 or
RB51-QAE, a TSI test was performed. The results were read at the same time as the H2S
test by observing the media for changes in color and the production of gas bubbles.
Dye sensitivity tests were performed for each strain using Thionin and Basic
Fuchsin. Plates were made using agar containing either Thionin or Basic Fuchsin (Hardy
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Diagnostics) then streaked with suspected colonies from RB51 or RB51-QAE that had
been suspended in a sterile saline solution. A positive control plate was also prepared.
Each plate was incubated at 37°C in a 5% CO2 atmosphere for a period of 3-4 days to
allow for adequate growth. The results were determined by the presence or absence of
growth in the presence of Thionin and Basic Fuchsin.
Serological Examination
A blood sample from each of the test animals was taken prior to infection and at
the time of sacrifice. These samples were spun down and the serum extracted. The
Brucellosis Card Test (Obtained from USDA, APHIS, manufactured by Becton
Dickenson and Co.) was performed for each of the pre-bleed samples as well as for each
of the post-inoculation samples. A 30μl volume of Buffered Brucella Antigen (BBA)
(Becton Dickinson and Co.) was placed onto a Brewer Diagnostic Card (Becton
Dickinson and Co.) with a 30μl sample of serum from each goat. A sterile toothpick was
used to mix each serum sample with the BBA until a uniform suspension was achieved.
The samples were then rocked for a period of 4 minutes and observed for agglutination.
The serum from each goat was also used to perform western blots on all pre-bleed
and post-inoculation samples for the purpose of monitoring the antibody immune
response for each animal. The blots included lysates of both RB51 and RB51-E, as well
as several other strains of Brucella, both rough and smooth.
Cell lysates of B. abortus 2308, B. abortus RB51, B. abortus RB51-QAE, B.
melitensis 16M, B. suis VTRS-1, Y. enterocolitica 0:9. and Y. enterocolitica 0:8 were
prepared for western immunoblots through the method of sonication. For sonication,
each species of bacteria were grown on selective media plates. Each culture was
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incubated for 2-3 days at 37°C in a 5% CO2 atmosphere. The bacteria were harvested
using 2 ml of sterile PBS (Sigma Chemical Company) for each plate. Each volume of 2
ml was sonicated using a Heat Systems-Ultrasonics W-385 Sonicator (Farmingdale, NY)
for 8 minutes with a 50% duty at a 1-second pulse and a 4.0 to 4.5 output. A loop of the
resultant lysates were spread onto one half of a selective media plate and the rest boiled
for 10 minutes. A loop of the sonicated and boiled lysates were spread on the second half
of the selective media plate and allowed to incubate for 2-3 days to confirm that the
Brucella cell lysates are no longer viable. To prepare the lysates for western
immunoblotting, a 150μl volume of lysate was mixed with a 150μl volume of Laem mli
Sample Buffer (BioRad Laboratories) prepared with a 0.1 volume of 2-mercaptoethanol
and boiled for an additional 10 minutes.
Coomassie staining was used to determine the ideal volume of each lysate to be
used in polyacrylimide gel electrophoresis (SDS-PAGE). Based on these results,
volumes between 3 and 5μl of each lysate was loaded onto a precast 12% Tris-HCl Ready
Gel (BioRad Laboratories) with a Kaleidescope Prestained Standard (BioRad
Laboratories) size standard marker. The gels were run in a Criterion Precast Gel System
(BioRad Laboratories) at 150V for a period of 1 hour and 15 minutes to 1.5 hours until
the dye front reached the bottom of the gel.
Proteins were transferred to a nitrocellulose membrane (Osmotics, Livermore,
CA) at 100V for 1 hour at 4°C. The membrane was blocked in a 5% solution of Blotting
Grade Blocker Nonfat Milk (BioRad Laboratories) in Tris-Buffered Saline (0.5M NaCl,
20mM Tris) (TBS), incubated for 1 hour on a rocker at room temperature, washed with
TBS-Tween (TBS, Tween-20) 5 times and once with TBS. Each individual blot was
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incubated overnight in a 1:40 dilution of test serum on a shaker at room temperature, and
washed again as before. The immunoblots were immersed a 1:800 dilution of rabbit antigoat IgG horseradish peroxidase (Sigma-Aldrich Co., St. Louis, MO) on a shaker in room
temperature for 45 minutes. Blots were developed in a TBS-methanol-3% hydrogen
peroxide solution using 4-chloro-1 napthol tablets (Sigma-Aldrich Co.) for visualization,
stopped in dH2O, and air dried.
Histopathological Analysis
Histopathology was performed by Dr. Eric Snook at the School of Veterinary
Medicine, Louisiana State University. Tissue samples from necropsy were fixed in 10%
neutral buffered formalin and embedded in paraffin. Each slide was stained using
hematoxylin and eosin then examined for pathology.

Results
Creation of B. abortus RB51-QAE
The resultant colonies that grew on the BA-Amp plates following electroporation
were subjected to further testing in order to ensure that the surviving colonies were
Brucella spp. and carried the pQAE DNA with the region E gene (Figure 1 A & B). All
colonies tested catalase, oxidase, and urease positive, confirming the colonies as Brucella
spp. A plasmid isolation miniprep was performed on the suspect RB51-QAE colonies
and further tests such as PCR and restriction enzyme digestion, both targeting region E of
the plasmid DNA, were used for confirmation. Sequencing information obtained for
pQAE was analyzed and confirmed the presence of the region E gene sequence in pQAE.
The resultant plasmid DNA from the miniprep procedure was run on an agarose
gel with a size standard and a positive and negative control, stained with ethidium
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(A) Region E Gene Sequence
GAATTGGCGACCTGACTGAGGATAGCGGCACAAATACGGCTGCAGTCAGCGGCAATACCATTCGCGCCC
AGACGATCGTGAATGATAGTTCTAATACCCTTGAAGGAAAACTGTCGGACGACTATGCGTCATCAACGTT
GGGTACCTCTTCCTTAACCTTTGGGACTCCTTTCGGATTGGAACCTCGGCATGTAACTCAGGGGGCAATCC
TGGCAGAAACGGCGCAGATAAACATTGCAACCGGCCATAAGGCGACGGTTTCCGAGGGCATAATAGGAA
CCCAGAATACGGCAAAACAAGAGGTGGCCGCTGGGGCAAGCCTCAGTCTGCAAGAAAATACTATTGATG
CTTCGCTTGCCGTCAACAATGCGGCGAACAGGATTGCCATCGACAAGGAAGGCGATCCGACTTTCCAAG
GCTCGGTCCTTATTACCAATCTGCAGCAGAACAAAGAGGGCTCTGTTGACGCAGAAACGACAGAGTCGG
GTATATTGGCGCAAGCGACAGAAGGAGATGTTGCGAATGTAATGTCTATTCTGTCGGGCAGTCTGAACGT
AGCGGAAAACATTGTTTCCAGTTCTGCAACCGGTAACCAGACCGTTGGTGCCGCAGGCGCCGCAGGTCAT
CAGATTGTGATCGGTGGTCAACTCAGCGTCGATAGCAATACTACCGGAAACGGCAGTTCAACGATATCGC
ATGACGGAGGCTCTGCATTTGCCGAAACCGCCGCTGACTTTGTTATTGCCAATAACCAGGCAAACATCGT
TACAGATGCGGCTGATCATTTGACAATCTCCAGCGCGTCTATTGGTGTGGAGGGTACACCGACGATTGGT
GCGGTTGTTGATGCCGTCGAAGGAGGTTCGGTTGTCCTCGCGGATAATGCCGTGACGTCTCAGGCGGTAG
GTAACAACACATCCGCCGCAATCTTGAAGGATGATGACTCCGCAGTCGGCTTTGATGCAACAGCTGCCCT
TGCTAACCATCAGATTAATCTGTTTTCTGATATTGCGGCGACCACGCAAAATGGCTCAGTGGTTGCCATTG
TCGGTAAAGCGAGAGACAGTATCTTCGATGAAGGGACCGTTGATGTTTCGGGGAACAAGATTTCCGCACT
GGCGTTTGGCAACAGCGCCAGCCAGCAGTTGGCCCTGGACGCCAATAACCTAACCGCTGGGGATAGCAC
TGGGTTGCTGACGGGCGGGCCGAACGACGAGACTACCCATGATAGCGGCCTTCGGGCTAAGGCAGGTGC
TATGCTTACCAGCCTACAGGCAAACTATAGCAGTGATATTTCCGCCAACAATGCGGCGTCGGTGGTTGGT
GTCTACGGCGACAACAAGGTTGGTAGCGACATATCTGGAGCCAAATTAACCGTCGAGAACAACACGCAG
CAGGCGACTGCGATTGGTAGCGACGCTACTAATCTGCTTGGACAAGTGCATTATGAGGACGGCAAGGCG
GATCATGTAGCCGGACTTGGCGGAAACAGTGTCGCCGGTTCGGCCGGTATTGCCAACGTTCAGGTGGGTG
ATGCTGGATCGTCGGTCATTGCTTCGTTGACCGATGCGGTCGCAGGATTCCCAGGAATCAGCAGTAGGGC
TCCCATAACGCTACCGTTTTTTAATGCCAACGTTAAACAGGAGGAATCCAGCTTTTCGGTAACCGACAAT
GTGCAGAGCGCCTCAGCCAGCGGCACCCAGAGCCGCAATGAACTGGTGGTCGAGAGCAATTCCGTCACT
GCCAATATTGGAACTGGTGCTCAAGAGCATCCCACTTCATCAAATACCGGTCTTGACGGAGCGTATGTAC
GCGATAACGAAGATAGTTTCCATACCATTCATCAGCCTATGATCATGGCGGCCTATGGCCTTATCAACGA
TCAGTCGATTGGGGGGAGAGTCAATGCCCTAGAACCTGTCTGCATTCAAGGATTCCCTTTTGTACGAAAT
TCTGATTCAAGGTTGTTAAAGGAGAACAGCCGTGAG

FIGURE 1
(A) Region E gene sequence with ORF-944F and ORF-944R primer sequences in red.
(B) Diagram of the pBBR1MCS-4
plasmid used to create pQAE.

(B)
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bromide, and analyzed under UV light. A band of approximately 4950 bp in length was
observed for all of the plasmid DNA tested, suggesting that the colonies in question
carried the 4950 bp pQAE (data not shown).
A PCR experiment was set up and run with primers (Orf944F and Orf944R)
targeting the region E portion of pQAE miniprep isolated from the suspect RB51-QAE
colonies. The resultant amplified DNA was run on a 1% agarose gel with a supercoiled
DNA molecular weight ladder and controls, stained, and analyzed under UV light. A
band of approximately 2000 bp was observed in each of the test sample lanes, confirming
the presence of region E in the plasmid DNA isolated from the suspect RB51-QAE
colonies (Figure 2).
For further confirmation, a restriction enzyme digest using EcoRV, targeting
region E, was also performed on the plasmid DNA from the colonies in question. The
digests were run on a gel with a size standard, controls, and the intact plasmid DNA of
each digested sample. The resultant gel produced bands of approximately 4950 bp in
length corresponding to the intact DNA, and bands of approximately 2000bp in length
corresponding to the lanes of digested DNA (data not shown). Therefore, the results of
this digest further confirmed the presence of region E in the plasmid DNA isolated from
the suspect RB51-QAE colonies.
Due to the results of the plasmid isolation and subsequent sequencing, PCR, and
restriction enzyme digest performed on the RB51-QAE colonies in question, it is
confirmed that the electroporation procedure was successful and that the resultant RB51QAE colonies carried the QAE plasmid containing the region E gene.
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Figure 2.
Agarose gel electrophoresis of plasmid minipreps performed on 3 suspected RB51-QAE
colonies amplified by PCR using the ORF-944F and ORF-944R primers and run by
agarose gel electrophoresis. The bands are approximately 2000bp in size, according to
the standard molecular weight marker shown.
The lane order is as follows:
Lane 1 – 1kb Molecular Weight Ladder
Lane 2 – Negative control group of dH2O
Lane 3 – PCR products from B. abortus RB51
Lane 4 - PCR products from miniprep DNA isolated from RB51-QAE suspect 1
Lane 5 - PCR products from miniprep DNA isolated from RB51-QAE suspect 2
Lane 6 - PCR products from miniprep DNA isolated from RB51-QAE suspect 3
Lane 7 – Positive control of PCR products from pQAE DNA
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Bacteriological Examination
In order to better characterize RB51-E, 10 general biochemical tests, including
dye sensitivities were performed for RB51-QAE, the standard RB51 vaccine strain, and
B. abortus 2308. The results of these tests for RB51 and 2308 matched the typical results
seen for RB51 and 2308. The results produced by RB51-QAE were identical to those
seen for the standard RB51 vaccine strain (Table 1).
To evaluate the colonization capabilities of RB51-QAE in the caprine host,
twenty non-pregnant goats were conjunctivally inoculated with 1×1010 colony forming
units (CFU) of either RB51-QAE or RB51. Following the necropsy of each animal at 7,
14, 21, 28, and 42 days post inoculation, each of the 6 tissues collected per animal were
homogenized and a portion of each tissue was plated onto a BS-BA plate as well
as a BA-Amp plate. The resultant colonies from each animal at each time of sacrifice
were counted and recorded. The overall culture results showed that the tissues from
animals inoculated with RB51-QAE yielded a significantly higher bacterial titer at 14, 21,
and 28 days post-inoculation than the tissues from animals inoculated with RB51. RB51QAE was also shown to survive longer in the host tissues than standard RB51 (Figure 3)
(Table 2). It should be noted that the results obtained for 14 days post-inoculation for the
RB51 group are not typical when compared to previous studies examining the survival of
RB51 in the caprine host. In most instances, RB51 is capable of surviving up to 21 days
post-inoculation. The absence of RB51 in the 14 day post-inoculation group could be
due to errors in vaccine administration or deficiencies within the animals tested.
Only one confirmed Brucella colony was detected for either group at 42 days post
inoculation (Table 2). This CFU was observed for an RB51 animal, but after further
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Table 1.
Results of ten biochemical tests performed on 2308, RB51, and RB51-QAE. The results
for 2308 and RB51 were expected and consistent with previous findings. RB51-QAE
produced results similar to RB51, indicating that the addition of the pQAE plasmid did
not make RB51-QAE biochemically dissimilar to the parental strain.

Test

Gram
Serum
Basic
R or S Stain AgglutinationAcriflavinOxidaseCatalaseUrease H2S TSI Thionin Fuschin

2308

Smooth neg

+

–

+

+

+

+

–

–

+

RB51

Rough neg

–

+

+

+

+

+

–

–

+

RB51-QAE Rough neg

–

+

+

+

+

+

–

–

+
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Figure 3. Colonization of male and non-pregnant female goats with RB51 and RB51QAE in average CFU/gm of tissue from parotid and prescapular lymph nodes taken at 7,
14, 21, 28, and 42 days post inoculation. Significance considered at p<0.05.
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Table 2. Colonization of goats with B. abortus RB51 and B. abortus RB51-QAE in
Parotid Lymph Nodes, Prescapular Lymph nodes, Liver, and Spleen

7 DPI

Animal
#

Received

Card
Test

Par LN

CFU/g

O-26

RB51

negative

37

3.72E+03

26

negative

4

8.19E+02

negative

40

4.58E+03

Y-32

RB51
RB51QAE
RB51QAE

negative

62

2.46E+03

O-30

RB51

negative

Y-28

O-07

RB51
RB51QAE
RB51QAE

O-14
Y-19

O-20

14 DPI

negative

No
Growth
No
Growth

–

negative

250

3.55E+04

negative

4

7.05E+02

RB51

negative

No
Growth

–

negative

4

9.12E+02

negative

315

2.36E+04

Y-23

RB51
RB51QAE
RB51QAE

negative

200

3.11E+04

Y-06

RB51

negative

O-08

negative
negative

8

G-54

RB51
RB51QAE
RB51QAE

No
Growth
No
Growth

negative

O-24

RB51

negative

PD3

RB51
RB51QAE
RB51QAE

negative

Y-08

21 DPI

O-29

28 DPI

Y-07

42 DPI

O-23
Y-27

negative
negative

–

PreS LN
No
Growth
No
Growth
No
Brucella
No
Growth
No
Growth
No
Growth
1
No
Growth
No
Growth
No
Growth
1
No
Growth

2.77E+03

No
Growth
No
Growth
No
Brucella

39

6.41E+03

7

1
No
Brucella
No
Brucella
No
Growth

1.09E+02

–
–

–
–
–
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No
Brucella
No
Growth
No
Brucella
No
Growth

CFU/g

Liv/Spl

CFU/g

–

2

4.22E+01

–

1

2.36E+01

–

1

2.00E+01

–

1

1.98E+01

6.43E+01

No
Growth
No
Growth
No
Growth

–

–

1

2.20E+01

–
–

–
–

–

No
Growth
No
Growth

5.03E+01

1

1.97E+01

–

6

2.31E+01

–

–
–

–

No
Growth
No
Brucella
No
Brucella

–

5.09E+02

6

2.33E+02

–
–

–
–
–
–

No
Brucella
No
Brucella
No
Brucella
No
Growth

–
–

–
–
–
–

testing by plasmid isolation and PCR analysis, it was found to be an RB51-QAE colony.
It was assumed that this colony was the result of a contamination during necropsy.
Serological Examination
Each of the animals used for this study were subjected to pre-inoculation and
post-inoculation serum testing. A pre-inoculation serum sample and a post-inoculation
serum sample, taken at the time of sacrifice, were tested for each animal by a standard
brucellosis card test. Each of the animals tested negative before and after inoculation for
Brucella-specific smooth antibodies. The pre and post inoculation samples were used to
run a set of western blots for each animal. The western blots contained the lysates of B.
melitensis 16M, B. suis VTRS-1, B. abortus 2308, RB51, RB51-QAE, B. ovis, and B.
canis. The results of RB51-QAE inoculated goats on the western immunoblot assay
yielded an equal or greater humoral immune response in the goats tested as compared to
blots run for RB51 goats during the same time points (Figure 4).
Histopathology
There appeared to be no definitive histological pattern in the liver and spleen with
respect to the time or type of infection in any animal. At day 28, the RB51 group
subjectively appeared to have an increased follicular activity as compared to RB51-QAE
in some lymph nodes. At day 42 the RB51-QAE group had a subjectively increased
follicular activity over RB51 (data not shown).

Discussion
In 2007, Perry hypothesized that addition of the Region E sequence via the pQAE
plasmid to B. abortus 2308 would increase virulence in the caprine model and that the
absence of Region E from B. melitensis 16M would cause attenuation in the caprine
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21 days post-inoculation

28 days post-inoculation

1 2 3 4 5 6 7

42 days post-inoculation

Figure 4.
Characteristic western immunoblots showing an increase in humoral response in goats
inoculated with RB51-QAE. These results are from representative goats sacrificed at 21,
28, and 42 days post-inoculation. The first blot in each group shows the results of a preinoculation sample and the second shows the results of the post-inoculation sample taken
during necropsy on the days specified.
The order of lysates, as follows, is numbered on the first blot of this figure and the same
order remains throughout:
1.
2.
3.
4.

B. melitensis 16M
B. abortus 2308
B. suis VTRS-1
B. abortus RB51-QAE

5. B. abortus RB51
6. B. canis
7. B. ovis
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model described by Elzer et al. in 2002. It was demonstrated that the addition of Region
E to B. abortus 2308 resulted in a significant increase in colonization and pathogenicity
in goats, when conjunctivally inoculated. The B. melitensis 16M Region E deletion
mutant (16MΔE) did not cause decreased colonization when compared to the parent
strain, but did result in a decrease in pathogenesis in the caprine host (Perry 2007).
Further investigation of the Region E protein as a putative hemagglutinin and host
specificity factor was merited.
This study uses the caprine model to test the effects of the Region E gene addition
to B. abortus RB51 (RB51-QAE) . Furthermore, the characterization of the Region E
protein as a putative hemagglutinin, cell surface protein, host specificity factor, and
immunogenic determinant was explored. It was hypothesized that addition of the Region
E protein, via pQAE, would increase virulence of RB51 in the caprine model described
by Elzer et al. in 2002. It was also proposed that the Region E protein was a cell-surface
hemagglutinin and host specificity factor capable of inducing anti-Region E protein
antibodies in the caprine host. Both the parental strain of RB51 and the RB51 region E
variant (RB51-QAE) were examined in the caprine host for effects on colonization using
both male and non-pregnant female goats. The hemagglutinating abilities of the region E
protein were evaluated using RB51 and RB51-QAE in a hemagglutination assay
examining cell harvest, broth culture, and supernatant samples using both goat and cow
erythrocytes. Absorption assays were also performed using serum from goats infected
with comparison strains of Brucella with and without the presence of the Region E gene
sequence (specifically, 16M and 16MΔE, 2308 and 2308-QAE, RB51 and RB51-QAE).
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The RB51-QAE mutant was examined using ten biochemical tests (described
previously) and it was demonstrated that the addition of pQAE did not make the
organism biochemically different from the parental strain. When subjected to a Rose
Bengal card test, serum from neither experimental group provided positive test results.
This indicates that the addition of pQAE to B. abortus RB51 did not result in converting
the strain from rough to smooth. Furthermore, a noticeable increase in humoral detection
by western immunoblots was observed when compared to the parental RB51 strain,
suggesting that RB51-QAE has an increased immunogenicity when compared to the
parental strain.
The addition of pQAE provided RB51-QAE with specific attributes that may have
enabled the organism to increase its colonization in a caprine host. At day 7 postinoculation, both RB51 and RB51-QAE successfully colonized the parotid lymph nodes
and were detected in the liver and spleen. This outcome was typical of an RB51
colonization in the caprine model. At day 14 post-inoculation, only RB51-QAE was
cultured from necropsy. None of the RB51-inoculated animals produced Brucella
colonies from any of the tissue samples tested. This may be due to an error in sample
collection, sample preparation, or bacteriologic technique. Additionally, this result may
also be attributed to inoculation errors or physiological issues involving the animal itself.
Typically, RB51 is able to colonize tissues of the caprine host for approximately 21 days
post-inoculation, which further supports our day 14 post-inoculation results as erroneous
(Adone et al. 2005, Neilson et al. 2004). As shown by the day 21 post-inoculation
animals, RB51 continued to colonize the parotid lymph nodes in the animals tested,
indicating the erroneous nature of the day 14 post-inoculation findings. In this same
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group, the RB51-QAE goats sacrificed at 21 days post-inoculation were identified in the
parotid lymph nodes, the prescapular lymph node, and in liver and spleen tissues. In
addition, only RB51-QAE was cultured from the day 28 post-inoculation animals,
supporting the proposal that RB51-QAE is able to survive for a longer period in the
caprine model than the parental strain. On day 42 post-inoculation, no significant culture
growth was detected from any of the animals or tissues tested. A single colony was
detected and confirmed as RB51-QAE, but this result is not significant.
The results of the tissue culture assays show that RB51-QAE is able to colonize
the host more effectively than the parental strain RB51. The results of this experiment as
a whole merit further investigation into the function of RB51-QAE as a vaccine
candidate. Future studies to determine the pathogenicity and, subsequently, vaccine
efficacy in goats and other primary host and reservoir animals are currently in planning.
Because smooth vaccines interfere with diagnostic tests and are an obstacle to eradication
efforts, a rough vaccine applicable in goats and would be a useful tool in reducing the
disease in endemic countries.
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CHAPTER TWO
CHARACTERIZATION OF A PUTATIVE
HEMAGGLUTININ OF BRUCELLA MELITENSIS
EXPRESSED BY THE REGION E GENE
Introduction
Determining the functional characteristics of the protein expressed by the region
E gene is important in evaluating its role in the increased colonization capabilities of
RB51-QAE in the caprine host. Strains of B. abortus lack the region E gene and are not
as effective in colonizing goats as strains of B. melitensis, which naturally express the
region E gene. The region E protein was shown to increase colonization of both B.
abortus 2308-QAE and RB51-QAE in goats, suggesting that the addition of region E may
confer host-specificity to strains of B. abortus in the caprine host. The protein expressed
by region E is referred to as a putative hemagglutinin and cell wall surface protein when
examined through a BLAST search.
In evaluating the potential of RB51-QAE as an improved vaccine candidate, it is
important to determine if the protein is expressed by RB51-QAE and, if expressed, the
functional aspects of the region E protein in the caprine host. Two-dimensional gels were
created and mass spectrometric analysis was used to determine expression of the region E
protein in RB51-QAE and a strain of E. coli DH5α that has been made to express the
region E gene (DH5α-TOPOE), but the protein was not detected in the gels.
Hemagglutination assays were prepared with bacterial strains expressing pQAE to
evaluate the hemagglutinating capabilities of region E protein. The immunogenic
characteristics of region E were assessed using western blot absorption analysis using
serum from goats inoculated with strains of Brucella expressing the region E gene.
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Materials and Methods
Preliminary Characterization
The region E gene was analyzed using the NCBI Basic Local Alignment Search
Tool (BLAST) and the B. melitensis genome surrounding region E was examined using
the Kyoto Encyclopedia of Genes and Genomes (KEGG) online database.
Bacterial Preparations for Hemagglutination Assay
The strains of bacteria studied in the hemagglutination assay were chosen based
on the presence or absence of the region E protein in the genome and tested against
mutant strains that either contained a plasmid expressing the region E gene, or a deletion
mutant that is devoid of the region E gene sequence. The bacterial strains used are as
follows: B. abortus RB51 & B. abortus RB51-QAE and E. coli DH5α & E. coli DH5αTOPOE. Previously stored cell lysates for all of the strains tested were subjected to
hemagglutination assays using goat erythrocytes. Both strains of E. coli DH5α were
grown previously and stored in glycerol stocks at -80°C. DH5α-TOPOE expresses the
TOPOE plasmid, which is a high-expression vector that contains a copy of the region E
gene as well as a kanamycin resistance gene for selection. To confirm the presence of the
region E gene in the TOPOE plasmid, the plasmid was sequenced using BioMMED
(Baton Rouge). Both B.abortus RB51 and RB51-QAE lawns were grown as previously
described on selective SBA plates, with RB51-QAE being grown on plates containing
ampicillin at a concentration of 1μl/ ml media. Two series of SBA plates were prepared
with one set containing bovine blood and the second containing caprine blood. Both
RB51 and RB51-QAE were grown on both sets of blood SBA plates and harvested in 2
ml of sterile PBS (Sigma Chemical). Both E. coli DH5α and E. coli DH5α-TOPOE were
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grown on LB agar media and similarly harvested. The LB agar plates used to grow
DH5α-TOPOE were prepared with a 1μl/ ml media concentration of kanamycin for
selective purposes. All cell suspensions were analyzed by spectrophotometer at an
OD600nm reading of 0.75 to equalize cellular concentrations of each experimental group.
Each sample was then subjected to hemagglutination assays.
Broth cultures were also prepared for each of the RB51 and DH5α strains in 2 ml
of broth in a 15 ml centrifuge tube. B. abortus bacteria were grown in brucella broth
(Becton Dickinson and Co.). Ampicillin was added to the broth culture containing
RB51-QAE at a concentration of 100 μg/ ml of broth. Control tubes were also set up
with one control brucella broth culture containing no specimen and a brucella broth
culture containing ampicillin inoculated with RB51. Broth cultures for E. coli were
prepared in LB broth. Kanamycin was added to the broth culture containing DH5αTOPOE. A control tube was prepared with LB broth and no added inoculate. A second
control was also prepared using LB broth containing kanamycin at a concentration of
45μg/ ml of broth and inoculated with DH5α. Each culture was placed in a water bath set
to 37°C with moderate agitation. The E. coli cultures were allowed to incubate
overnight, and the B. abortus cultures were allowed to incubate for a period of 3 days.
Following incubation, a 500ul portion of culture was separated and centrifuged. The
supernatant was separated and subjected to a hemagglutination assay. The remaining
broth culture was subjected to a hemagglutination assay as a whole.
Erythrocyte Preparation
Erythrocytes from both bovine and caprine sources were used for the
hemagglutination assays to assess the host-specificity of the putative hemagglutinin. A
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blood sample was collected using a 10 ml BD Vacutainer tube (Becton Dickinson and
Co.) containing EDTA as an anticoagulant. The sample was mixed and aliquoted into
500μl portions in sterile 1.5 ml micro centrifuge tubes. The contents of each tube were
centrifuged at 3000rpm for 3 minutes, the plasma was drawn off, the erythrocyes were
sspended in 500μl of sterile PBS. This rinsing step was repeated 4 additional times and
the final erythrocyte suspension was stored for no more than 3 days at 20°C. Both
caprine and bovine erythrocytes were prepared and stored in this manner and used to
make a 2% solution for each of the hemagglutination assays.
Hemagglutination Assay Technique
Hemagglutination assays were prepared in 96 Well “U” Bottom Plates (Corning
Incorporated, Corning, NY) containing 100μl sterile PBS per well with (Sigma
Chemical) 200μl of each cell suspension or culture sample in the first well of the series.
Two fold dilutions were made by adding 100μl of the initial sample into 100μl of PBS in
the next well and 100μl of either bovine or caprine erythrocytes were added to each well.
A control of PBS was also included. The samples were allowed to incubate overnight.
A hemagglutination assay using only the supernatant from each broth culture was
also prepared to assess localization of hemagglutinating factors as either cell associated
or secreted using similar techniques. The supernatant samples were not adjusted
according to OD600nm calculations, as readings were identical, suggesting that a
comparable amount of supernatant proteins were already present in each sample.
Visual Analysis
Plates were read visually according to the presence of a button or matte in the
well, the size and color of each button present, and the color and clarity of the PBS
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suspension in each well. Because the bacterial cells settled to the bottom of the well,
each plate was read from the bottom.
Absorption Assay
Absorption assays were performed to detect host antibodies to the region E
protein by way of western immunoblot for the purpose of further characterizing the
region E protein as it is expressed in vivo. Samples were obtained from goats previously
infected with B. abortus 2308-QAE, B. melitensis 16M, and B. abortus RB51-QAE. The
serum from goats infected with strains of 2308-QAE and 16M were from a previous
experiment performed in this lab and the serum sample from the RB51-QAE goat was
from the colonization experiment previously described.
An amount of 1 ml of each serum sample was combined with 1 ml of 2308 (for
2308-QAE), RB51 (for RB51-QAE) and 16MΔE (for 16M) lysates in a sterile
microcentrifuge tube. The tubes were then placed on a rocker for 2 hours to allow
absorption of Brucella-specific antibodies. The tubes were removed from the rocker,
centrifuged at full speed for 5 minutes to pellet cells, then the remaining serum was
drawn off for western blot analysis.
The western blot analysis to detect antibody to the region E protein was
performed as previously described and the lane order was as follows: a size standard
marker, RB51, RB51-QAE, 2308, 2308-QAE, 16MΔE, and 16M. The western blots
were analyzed visually following development.
Membrane Isolation
Two dimensional gels were run for both B. abortus RB51 and RB51-QAE as well
as E. coli DH5-α and DH5-α-TOPOE. Whole cell lysates were used for all species and
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purified membrane components were obtained for DH5-α and DH5-α-TOPOE. To
isolate membrane components for DH5-α and DH5-α-TOPOE, a 5×108 CFU/ ml culture
was grown overnight at 37°C. Cells were pelleted and resuspended in .75M sucrose10mM tris. Lysozyme and EDTA were added to the suspension and the cells were
pelleted. The supernatant was drawn off and ultracentrifuged at 60,000 rpm to isolate
membrane portions.
2D Gel Analysis
Protein samples were cleaned using the Ready Prep 2D Cleanup Kit (BioRad
Laboratories). One hundred μl of each lysate was mixed with 300μl precipitating agent 1
(BioRad Laboratories), then incubated on ice for 15 minutes. Three hundred μl of
precipitating agent 2 (BioRad Laboratories) was added and the tubes were centrifuged at
14,000 rpm for 5 minutes for pellet formation. The supernatant was removed, 40μl of
wash reagent 1 (BioRad Laboratories) was added to the pellet, which was centrifuged at
14,000 rpm for 5 minutes. Next, 25μl of Ready Prep proteomic grade water (BioRad
Laboratories) was used to resuspend the pellet. One milliliter of pre-chilled wash reagent
2 (BioRad Laboratories) was added with 5μl of wash 2 additive (BioRad Laboratories)
then vortexed for 1 minute. Each tube was incubated on ice for 30 minutes, with a 30
second agitation every 10 minutes during incubation. The tubes were centrifuged at
14,000 rpm for 5 minutes to form a pellet. The pellet was allowed to air dry at room
temperature then resuspended using 2D Rehydration buffer (BioRad Laboratories). The
samples were centrifuged at 14,000 rpm for 5 minutes. The supernatant was drawn off
and run on Immobilized pH Gradient (IPG) strips (BioRad Laboratories).
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Protein samples were loaded onto a focusing tray and the thawed IPG strips were
placed gel side down onto each sample. An Isoelectric Focusing apparatus (IEF)
(BioRad) was programmed previously according to instruction and the IPG strips were
allowed to run overnight. Each strip was removed from the IEF, blotted, and transferred
to an equilibration tray. The strips were covered with 2 ml Equilibration Buffer I
(BioRad Laboratories) and placed on a rocker for 15 minutes. The equilibration step was
repeated with Equilibration Buffer 2 (BioRad Laboratories). The strips were blotted then
rinsed in Tris-Glycine-SDS (TGS) running buffer. Each IPG strip was placed into the
well of a precast gel cassette (12.5% concentration) using flat pliers until complete
contact was made between the strip and the bottom of the gel. A protein size standard
was loaded and the gels were run at 10mA until the dye front reached the bottom of the
gel. The gel was placed in a fixative solution (10% methanol, 7% acetic acid) and rocked
for 1 hour. The fixative was removed and the gel stained in SYPRO Ruby Stain (BioRad
Laboratories) overnight. The stain was removed and the gel was destained for 1 hour.
The gel was washed 3 times with dH2O and imaged using a UV transilluminator.
Comparisons between the gels were made and unique spots excised. The excised
spots were placed in 50 ml of sterile dH2O and agitated until dissolved. The tubes were
stored at -4°C until sent off for mass spectrometry analysis. The results of this analysis
were analyzed using NCBI BLAST to determine similarity to the region E protein.

Results
Preliminary Characterization
According to BLAST searches, the region E gene was found to have homology
with a putative hemagglutinin and cell surface proteins found in B. melitensis, B. suis, B.
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ovis, B. canis, B. ceti and B. pinnipedialis. Examination of the genes surrounding region
E on the genome showed coding regions for putative transposases or putative transposase
subunit proteins upstream, downstream, and overlapping the region E gene (Figure 5),
indicating that the putative gene is monocistronic and may be a pathogenicity island
delivered to B. melitensis by horizontal gene transfer.
Cell Lysate Hemagglutination Assay
Sonicated lysates for RB51, RB51-QAE, DH5-α, and DH5-α-TOPOE were used
in a series of hemagglutination assays using caprine erythrocytes. Each plasmid, both
pQAE and TOPOE, were sequenced and the presence of the region E gene in each was
confirmed. Each of the lysates were serially diluted in PBS and equalized in density
using spectrophotometric analysis. A 1 ml portion of each lysate was centrifuged and the
supernatant was drawn off and used in a hemagglutination assay. Caprine erythrocytes
were washed and a 2% erythrocyte solution was prepared on the day of assay preparation.
A PBS control was included for both lysate and supernatant assays. Each assay was
allowed to incubate at room temperature overnight.
None of the lysates from any species or strain showed any differences in
hemagglutination capabilities. Each differed from the PBS control because of the
presence of cellular debris in the well. A dark button of erythrocytes was seen in each
well, under the cellular debris. It was concluded that all of the lysates tested were
hemagglutination negative. Buttons were also observed in the assays studying the
supernatants from each of the lysates, confirming that the supernatants were also
hemagglutination negative (Table 3).
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Figure 5.
Map showing the coding regions of the Brucella melitensis 16M genome 1000bp
upstream and 1000bp downstream of the region E gene.
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Table 3. Hemagglutination results observed for RB51, RB51-QAE, DH5-α, and DH5-αTOPOE using both bovine and caprine erythrocytes.
Bovine Blood Agar

Caprine Blood Agar

LB Agar

Brucella Broth

Culture Supernatant

ND
HA+ to 1:16
dilution
NP

NP

NP

NP

DH5-α

ND
HA+ to 1:8
dilution
NP

NP
ND

NP
ND

DH5-α-TOPOE

NP

NP

NP
ND
HA+ to 1:16
dilution

ND

ND

ND
HA+ to 1:32
dilution
NP

NP

ND

ND

DH5-α

ND
HA+ to 1:16
dilution
NP

ND
ND

ND
ND

DH5-α-TOPOE

NP

NP

NP
ND
HA+ to 1:16
dilution

ND

ND

Bovine
Erythrocytes
RB51
RB51-QAE

Caprine
Erythrocytes
RB51
RB51-QAE

ND
NP

None Detected
Not Performed
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Bacterial Cultures
Broth cultures were prepared for RB51, RB51-QAE, DH5-α, and DH5-α-TOPOE.
Both strains of RB51 were cultured in brucella broth. An amount of 45μg/ ml of
ampicillin was added to the broth culture of RB51-QAE and to a control culture of RB51.
LB broth was used to culture both strains of DH5-α, and DH5-α-TOPOE. An amount of
1μl/ ml of kanamycin was added to the broth culture of DH5-α-TOPOE and to a control
culture of DH5-α. A 1 ml portion of each broth culture was centrifuged at high speed and
the supernatant was used to prepare serial dilutions in PBS for hemagglutination assays.
The broth cultures were equalized using spectrophotometric data and serial dilutions were
prepared in sterile PBS. Fresh preparations of 2% caprine and bovine erythrocytes were
used.
Clarity and size of button were similar across RB51 and RB51-QAE for both
species of erythrocytes tested. The only difference appeared to be button color
differences that corresponded to the presence or absence of region E protein. The buttons
observed for the RB51-QAE cultures were dark red in color, which differed from those
observed for the last 5 dilutions of RB51 and all of the dilutions of PBS, which were a
lighter red in color. However, because of the presence of these buttons, all assays for
both RB51 strains using both caprine and bovine erythrocytes were considered
hemagglutination negative. There appeared to be no visible difference between the
control PBS dilutions and the supernatants from both RB51 and RB51-QAE cultures. All
supernatant cultures were considered hemagglutination negative.
For cultures of DH5-α and DH5-α-TOPOE, there were no visible differences
between strains in either color or clarity across both caprine and bovine erythrocyte
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preparations. A button was observed for each dilution of culture as well as for each
sample of supernatant tested. All DH5-α and DH5-α-TOPOE cultures and supernatants
were considered hemagglutination negative (Table 3).
Bacterial Harvests
Fresh bacterial lawns of RB51, RB51-QAE, DH5-α, and DH5-α-TOPOE were
grown on selective media, harvested in sterile PBS, and subjected to hemagglutination
assays using both caprine and bovine 2% erythrocyte preparations. RB51 and RB51QAE were grown on brucella selective blood agar plates. Two series of plates were used
to grow both RB51 strains with one series produced using caprine blood and the other
produced using blood from a bovine. Ampicillin was added to the plates used to culture
RB51-QAE. DH5-α and DH5-α-TOPOE were grown on LB agar plates. Kanamycin
was added to the plates used to culture DH5-α-TOPOE. The harvests were equalized in
density according to spectrophotometric analysis.
Using caprine erythrocytes, a clear difference was seen between the
hemagglutination assays for RB51 and RB51-QAE. Cellular sediment was seen in each
well across all dilutions for both strains. A clear demarcation between RB51 cells and
erythrocytes was observed as a dark ring of erythrocytes atop a light mass of cells across
dilutions. For the sediment of RB51-QAE, there was no demarcation between cells and
erythrocytes. Instead, a uniform mass was observed for the first 5 dilutions of RB51QAE harvests, which were considered hemagglutination positive (Figure 6).
Using bovine erythrocytes, similar results in button consistency were seen for
both RB51 throughout each dilution and for RB51-QAE for the first 4 dilutions. For this
reason, the first 4 dilutions of RB51-QAE were considered hemagglutination positive.
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However, these differences were not as prominent as seen in the caprine erythrocytes.
For example, even though there was a more uniform grouping of cells for RB51-QAE,
there was still a hint of a light button present, which was not observed in the assays using
caprine erythrocytes.
Clear differences were observed between the RB51-QAE harvests for across
caprine and bovine erythrocytes. The caprine erythrocyte samples for RB51 appear
similar to the bovine erythrocyte samples for RB51. However, RB51-QAE in caprine
erythrocytes shows more hemagglutination properties to a greater extent (1 full dilution)
than RB51-QAE in bovine erythrocytes. These results were consistent across groups of
cells grown on both caprine and bovine blood agar plates (Table 3).
Cell harvests for DH5-α and DH5-α-TOPOE performed similarly in
hemagglutination assays as RB51 and RB51-QAE, respectively. The same demarcation
effect between erythrocytes and cells was observed for DH5-α dilutions across both
caprine and bovine erythrocytes. The first 4 dilutions of DH5-α-TOPOE harvests
resulted in a uniform mass of cells with no clear division between both caprine and
bovine erythrocytes and bacteria. These first 4 dilutions of DH5-α-TOPOE harvests were
considered hemagglutination positive for both bovine and caprine hemagglutination
assays. There was no clear difference between the assays using bovine and caprine
erythrocytes for DH5-α and DH5-α-TOPOE (Table 3).
Protein Characterization using Absorption Assay and 2D Gel Electrophoresis
For the absorption analysis assay, serum from goats inoculated with Brucella
species expressing the region E gene (2308-QAE, RB51-QAE and 16M) was absorbed
with the lysates from corresponding Brucella species lacking the region E gene (2308,
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Figure 6.
Assay comparing the hemagglutinating capabilities of RB51 and RB51-QAE using
caprine erythrocytes. Each sample was subjected to 1:2 serial dilutions made in sterile
PBS and mixed with 100μl washed caprine erythrocytes.
Row 1: Sterile PBS control
Row 2: RB51-QAE cell harvests
Row 3: RB51 cell harvests
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RB51, and 16MΔE). A unique band was observed on western immunoblots run with the
serum of goats inoculated with species of Brucella containing the region E gene that was
not present in those lanes containing the lysates of Brucella species lacking the region E
sequence. This band was approximately 74 kD in size, which is the approximately the
estimated size of the region E putative hemagglutinin protein. This unique banding was
seen especially for the RB51-QAE lysates on the immunoblot (Figure 7). Considering
that RB51-QAE is a rough strain, this effect may be due to increased exposure of the
region E protein due to a lack of OPS interference.
Lysates of RB51 and RB51-QAE as well as cell membrane isolates of DH5α and
DH5α-TOPOE, were analyzed using 2D electrophoresis. The resultant RB51 and RB51QAE gels were compared and a unique spot could not be identified (Figure 8). Because
of the complexity of the whole cell lysates, outer membrane fractions of DH5α and
DH5α-TOPOE were collected and subjected to 2D analysis (Figure 9). A single spot
with an isoelectric point and molecular weight of the region E hemagglutinin was
identified in DH5α-TOPOE, but mass spectrometric analysis of the sopt failed to confirm
a peptide map that matched.

Discussion
Genomic comparisons have been made between the region E protein and a 31kD
outer membrane protein found on the surface of B. suis (omp31), which has been
described as a cell surface heme-binding protein. Hemagglutination assays were
prepared to test the hemagglutination ability of RB51 versus RB51-QAE. It was
expected that RB51-QAE would have an increased effect on hemagglutination, as the
region E gene encodes for a putative hemagglutinin. Assays showed that at high
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5
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7

Figure 7.
Western Blot run with absorbed serum from a goat inoculated with RB51-QAE. The
serum was absorbed using RB51 previously. The unique banding pattern seen in the lane
containing RB51-QAE lysates indicates that the region E protein is capable of eliciting a
specific humoral response in goats when expressed by RB51. The unique bands are seen
between approximately 60 and 80 kD, according to the size standard in lane 1. Because
the estimated size of the region E protein is 68.94 kD, it is proposed that one of these
unique bands (designated by the red box) indicates antibodies specific for the region E
protein. The bands are observed in lanes 3 and 7 as well, but were too faint to appear
using our best imaging techniques. This may be due to phenotypic differences between
16M and 2308-QAE as compared to RB51-QAE.
The lane order is as follows:
1.
2.
3.
4.
5.
6.
7.

Size standard marker
B. abortus 2308
B. abortus 2308-QAE
B. abortus RB51
B. abortus RB51-QAE
B. melitensis 16MΔE
B. melitensis 16M
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2D image of B. abortus RB51

2D image of B. abortus RB51-QAE

Figure 8.
2D gel images taken of B. abortus RB51 and B. abortus RB51-QAE for the purpose of
identifying unique proteins produced by RB51-QAE. The complexity of the 2D gel
images of B. abortus RB51 and B. abortus RB51-QAE precluded the identification of a
unique spot for RB51-QAE that corresponded to the region E hemagglutinin. The top
image is of the 2D gel run with RB51 lysates and the bottom image is of RB51-QAE.
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2D image of DH5α isolated membrane

2D image of DH5α-TOPOE isolated membrane

Figure 9.
2D gel images were taken of E. coli DH5α and DH5α-TOPOE for the purpose of
identifying unique proteins produced by DH5α-TOPOE. The top image is of the 2D gel
run with DH5α membrane isolates and the bottom image is of DH5α-TOPOE membrane
isolates. The unique protein identified on the DH5α-TOPOE gel is outlined in red and
was analyzed by mass spectrometry.
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numbers, presence of the region E gene in the genome of RB51-QAE caused positive
hemagglutination in a 2% bovine and caprine erythrocyte solutions, whereas RB51 did
not. Furthermore, a higher incidence of hemagglutination was observed when subjected
to the assay using erythrocytes from goat blood, as compared to blood erythrocytes from
a cow. Also, a greater incidence of hemagglutination was seen when the RB51-QAE
tested was grown on media using goat blood rather than cow blood. This suggests that
not only is the region E protein a hemagglutinin, but it is also a host-specificity factor.
The hemagglutination assays for E. coli DH5α and DH5α-QAE were similar in that
positive hemagglutination was noted for the region E mutant, and not for the parental
strain. No agglutination was observed using cell broth culture supernatant for any of the
bacterial strains tested, suggesting that the hemagglutinating factor was not excreted from
the cell, but present on the surface. Further studies would be needed on a proteomic level
to further characterize the cellular location, hemagglutination and host specificity
capabilities of the region E protein.
The absorption assay performed indicated unique bands on western
immunoblots run with serum from goats inoculated with various strains of brucella both
containing and lacking the region E gene sequence. These unique bands, at
approximately 74kD, are of the approximate size of the putative hemagglutinin encoded
by the region E sequence. These bands were not present in the blot lanes for those strains
that did not contain region E. Specifically, this suggests that the immunogenic protein
produced by 2308-QAE, RB51-QAE, and 16M is recognized by the goat immune system
and is not produced by 2308, RB51, and 16MΔE. This indicates that the putative
hemagglutinin may increase the immunogenic capabilities of RB51 in the host animal,
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inducing the production of anti-region E protein antibodies. This is another finding that
supports the proposal that RB51-QAE would be an improved vaccine candidate when
compared to RB51.
There was a measureable difference in hemagglutination in isolates carrying the
region E clone, but the protein could not be identified in the 2D analysis. This could be
due to many factors, such as the region E protein being the same size and isoelectric point
as another RB51 protein or cluster or proteins, which would make the region E protein
indistinguishable from the other proteins. The 2D analysis of the pure protein would be
beneficial, but the exact size and isoelectric point of the region E protein are estimated at
this time, and not certain.
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CHAPTER THREE
EVALUATION OF PCR AS A DIAGNOSTIC TOOL FOR
BRUCELLOSIS
Introduction
The control of brucellosis as a worldwide disease relies upon effective
vaccination in animals and proper diagnostic testing. Human brucellosis, most often
contracted through interaction with infected animals, remains problematic in many
countries around the world. Because there is no vaccine for human use, control of human
brucellosis depends on accurate diagnosis and proper treatment. Currently, diagnosis of
brucellosis in humans involves serologic testing and confirmation through blood culture.
Although this is the diagnostic gold standard, there are issues involved with these
techniques that may hinder proper diagnosis. Serologic tests are subject to false-positive
results due to cross reacting antibodies and confirmation through culture may take weeks,
as Brucella spp. are slow growing organisms.
Methods of detection utilizing the polymerase chain reaction (PCR) are being
investigated for improved diagnosis. A reliable PCR technique would be quicker, easier,
and more affordable than current procedures while eliminating the possibility of false
positive reactions. Current research in this area, however, has been inconsistent. Results
differ based on biological sample type tested, DNA isolation methods used, and variation
in testing schedules.
In this study, the limit of detection of B. abortus 2308 and B. melitensis 16M was
examined using the Baily, Omp25, and ORF-944 Brucella-specific primer sets for
conventional PCR amplification and visualization using agarose electrophoresis. These
laboratory strains were diluted in fluid samples that may be taken for diagnostic purposes,
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including blood, plasma, serum, and urine. Optimization of DNA isolation technique and
thermalcycler protocols was also examined. The results of this study can aid in
continuing efforts to develop a reliable PCR technique for the purpose of improved
diagnosis of human brucellosis and increased control of the disease worldwide.

Materials and Methods
Bacterial Strains
B. abortus 2308 and B. melitensis 16M were studied in these PCR assays.
Bacteria were obtained using stocks of 1x1010 (2308) and 1x1011 (16M) colony forming
unit (CFU) concentrations and chloroform-killed. These cells were then serially diluted
to 1x101 CFU in sterile H2O, whole blood, plasma, serum, or urine and subjected to either
direct PCR amplification or DNA isolation and quantification.
One assay for the limit of detection of the region E gene sequence using the
region E primer set was performed using B. abortus RB51-E and 16M as template. For
this assay, bacteria were obtained as described above from previously prepared stocks of
1x109 CFU for RB51-QAE and 1x1011 CFU for 16M. These cells were serially diluted
ten-fold to 1x101 CFU in sterile H2O and subjected to PCR amplification using the region
E ORF-944F and ORF-944R primers following DNA isolation and quantification.
DNA Isolation
Two separate DNA isolation protocols were performed on the cellular dilutions
made in whole blood. The first protocol used was outlined in the Qaigen DNeasy Blood
and Tissue Handbook (Qaigen, Inc.) using the Qaigen DNeasy Blood and Tissue Kit
(Qaigen, Inc.). The second protocol used is the standard protocol used in lab, which also
utilizes the Qaigen DNeasy Blood and Tissue Kit (Qaigen, Inc).
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The first DNA isolation protocol was performed by mixing 50μl of a blood
dilution with 180μl buffer ATL (Qiagen, Inc.). A volume of 20μl of proteinase K was
added to the mixture, vortexed, and placed in a shaking water bath at 55°C for 1 hour.
Two hundred μl of buffer AL was added and the tubes were placed in a 70°C heating
block for 10 minutes. Two hundred microliters of 100% ethanol was added and the
samples were placed into a DNeasy spin column. A volume of 500μl of buffer AW1 was
added to the sample and centrifuged at 8000rpm for 1 minute. Five hundred μl of buffer
AW2 was added and the samples were spun at 14,000rpm for 3 minutes. The spin
column was placed into a clean 1.5 ml centrifuge tube, 200 μl of buffer AE was pipetted
onto the membrane of the spin column and allowed to incubate at room temperature for 1
minute. The samples were centrifuged at 8000 rpm for one minute. A second elution
step was repeated. The resultant isolated DNA was stored at 20°C until use.
The second DNA isolation protocol was performed by pipetting 50μl of a blood
dilution sample into a 1.5 ml centrifuge tube containing 20μl of proteinase K (Qiagen,
Inc.). The volume was adjusted to 220μl with sterile PBS (Sigma Chemical Co.). A
200μl volume of buffer AL (Qiagen, Inc.) was added to the tube, mixed by vortexing,
then incubated with agitation at 56°C for 10 minutes. Next, a volume of 200μl of 100%
ethanol was added, the mixture was loaded into a DNeasy spin column (Qiagen, Inc.),
and centrifuged at 8000 rpm for 1 minute. Five hundred μl of buffer AW1 (Qiagen, Inc.)
was added and the column was centrifuged at 8000rpm for an additional minute. Next,
500μl of buffer AW2 (Qiagen, Inc.) was added to the spin column and the samples were
centrifuged at 14,000rpm for a period of 3 minutes. The spin column was placed into a
clean 1.5 ml microcentrifuge tube and 200μl of buffer AE (Qiagen, Inc.) was added to the
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tube and allowed to incubate at room temperature for 1 minute. A second elution step
was repeated for maximum DNA collection. The tube was centrifuged for 1 minute at
8000rpm and the resultant flow-through was stored at 20°C until use.
The remaining groups (dilutions prepared in sterile H2O, plasma, urine, and
serum) were subjected to DNA isolation using only the first DNA isolation protocol, as it
proved to be a better technique for maximum isolate DNA collection.
Primer Selection and Preparation
The Omp25 primer set was designed using the Omp25 gene sequence of B.
abortus, which is highly conserved across Brucella spp., by Phillipe de Wergifosse et al.
(de Wergifosse et al., 1995). The first set of primers selected targets the Omp25 gene and
are designated Omp25F (5’ –GTTCCGGCTCCGGTTGAAGTA -3’) and Omp25R (5’ –
CGCGGATATCCTGCGTGTC -3’). The second set of primers were specific for 31 kDa
B. abortus antigen and designed to detect both B. abortus and B. melitensis (Baily et al.,
1992). The Baily primers were designated B4 (5’ – TGGCTCGGTTGCCAATATCAA3’) and B5 (5’- CGCGCTTGCCTTTCAGGTCTG- 3’). While both primer sets are used
to detect B. abortus and B. melitensis DNA, neither will differentiate between the two
species. A third set of primers was used for a limit of detection assay targeting the region
E gene sequence in 16M and RB51-QAE. The ORF-944F and ORF-944R primers were
used as previously described. Each primer set was synthesized by Integrated DNA
technologies, Inc. (Coralville, IA) and re-suspended using PCR grade H2O upon arrival.
Limit of Detection
Preliminary studies were performed using previously isolated DNA from B.
abortus 2308, B. abortus RB51-QAE and B. melitensis 16M. DNA was quantified using

91

the GE Healthcare RNA/DNA Calculator Spectrophotometer Model Gene Quant Pro
(Amersham Bioscience). A series of 1:10 dilutions were prepared in sterile H2O and
subjected to PCR using the Omp25 and Baily primer sets. A second set of 1:10 dilutions
was made for both Brucella species, but using known concentrations. Specifically, a
starting concentration of 1x1011 CFU/ ml of B. melitensis 16M and a 1x1010 CFU/ ml
starting concentration of B. abortus 2308 were both diluted ten-fold to a concentration of
1×101 CFU/ ml in sterile H2O. These preparations were also subjected to PCR using both
primer sets. Using the same 16M dilutions (1x1011 CFU/ ml to 1×101 CFU/ ml in sterile
H2O) and a set of similarly prepared RB51-QAE dilutions (1x1011 CFU/ ml to 1×101
CFU/ ml in sterile H2O), a limit of detection assay was performed using conventional
PCR and the region E ORF-944 primers. The resultant amplifications were subjected to
agarose gel electrophoresis and visualized as previously described.
Bacterial Sample Preparation
A total of 5 experimental groups were prepared for PCR analysis based on the
fluid used to dilute each of the samples. The first group studied the PCR detection
capabilities of the Omp25 and Baily primers on 2308 and 16M using colony forming
units (CFU) as template and isolated DNA diluted in sterile H2O. The detection
capabilities of the ORF-944 primers on RB51-QAE and 16M using DNA isolated from
CFU dilutions in sterile H2O was also studied. For all groups, samples were prepared
following chloroform killing. Serial dilutions of 1:10 were prepared in sterile H2O for
each Brucella species and each dilution was subjected to PCR individually. A 1.0 μl
portion was used as PCR template and the rest subjected to DNA isolation. The results
from this first group were used as a control for comparison of the remaining four groups.
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The next group consisted of chloroform killed CFUs from both 16M and 2308
diluted in whole blood. A series of 1:10 dilutions were made as described above with
both 2308 and 16M, but using whole blood obtained from an infection-free animal in the
place of sterile H2O. Similarly, a 1.0 μl sample of each dilution was used directly for
PCR and the rest underwent DNA isolation.
The remaining groups were prepared in a similar fashion, except using plasma,
urine, or serum in the place of whole blood. Each group was subjected to PCR using
CFU as template and to DNA isolation to use for PCR as a DNA template.
PCR Technique
PCR was performed as described previously using the FailSafe PCR System with
2X G Premix (Epicentre Biotechnologies) and a MyCycler Personal Thermal Cycler
(BioRad Laboratories). For amplification using the Omp25 primers, template DNA was
subjected to an initial denaturation step for 4 minutes at 95°C. Next, 34 cycles were
completed with denaturation at 95°C for 30 seconds, primer annealing at 65°C for 30
seconds, and elongation at 72°C for 2 minutes. A final elongation stage of 72°C was
performed for 10 minutes (Edmonds 2001). For amplification of the Baily primers,
template DNA was subjected to an initial denaturation step for 5 minutes at 95°C. Then
40 cycles were completed with denaturation at 90°C for 1 minute, primer annealing at
60°C for 30 seconds, and elongation at 72°C for 1 minute. A final elongation stage of
72°C was performed for 7 minutes. A second series of PCR assays were performed using
the same PCR preparations, but elongating each of the primer thermal cycler protocols by
5 cycles in an attempt to optimize amplification. This brought the total number of cycles
to 39 for the Omp25 protocol and 45 for the Baily protocol for these asssays (Baily
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1992). For amplification using the ORF-944 primers, the thermal cycler protocol was
performed as previously described. The resultant PCR amplifications were subjected to
Agarose gel electrophoresis for visualization as previously described.

Results
DNA quantification
Using previously made B. abortus 2308 and B. melitensis 16M stocks, a series of
nine 1:10 dilutions (ranging from approximately 1 μg/μl to 1×10-8 μg/μl) were prepared
for each in 100μl sterile H2O. The standard laboratory DNA isolation protocol described
previously was used to isolate DNA from each dilution. The DNA isolates of only 100%
concentration were quantified, as any dilutions were not quantifiable by the equipment
used. For the pure 2308 sample, a DNA quantity of 0.87 μg/μl was measured. For the
pure 16M sample, a quantity of 0.94 μg/μl was measured. The RB51-QAE sample
yielded a DNA quantity of 0.4x102 μg/μl.
The PCR amplification performed using the Omp25 primers and 16M DNA
provided a limit of detection of 1×10-4.05 , or 1:1000, of the original sample, which is
approximately 9.35x10-5 μg/μl. The PCR amplification performed using the Omp25
primers and 2308 DNA provided a limit of detection of approximately 8.72x10-6 μg/μl,
which is a 10-5 dilution of the original sample.
The PCR amplification performed using the Baily primers and 16M DNA
provided a limit of detection of 1×10-7.4 of the original dilution, which is approximately
9.35x10-8 μg/μl. The PCR amplification performed using the Baily primers and 2308
DNA provided a limit of detection of 1×10-7 of the original dilution, which is
approximately 8.72x10-8 μg/μl (data not shown).
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Using the ORF-944 primers and 16M DNA, a limit of detection was found to be
approximately 9.35x10-5 μg/μl. For the ORF-944 primers ad 2308 DNA, a limit of
detection was found at 4.0x10-6 μg/μl (Figure 10).
Thermal Cycler Protocol Optimization
In an attempt to optimize the standard thermal cycler protocols for both the Baily
and Omp25 primers, preliminary PCR assays were performed using the standard number
of amplification cycles for each primer set and an elongated protocol using 5 additional
amplification cycles for each primer set. It was observed that the elongated protocol
provided greater detection capabilities for both 16M and 2308 CFU and DNA than the
standard thermal cycler protocol for both primer sets. Specifically, for the PCR assays
using both 2308 and 16M CFU as template, the original thermal cycler protocol provided
a limit of detection at 1×108 CFU/ ml and the elongated thermal cycler protocol provided
a limit of detection at 1×105 CFU/ ml (for both 16M and 2308 using both primer sets).
Because of these results showing a 1000-fold increase in detection, the elongated
protocols were used for these PCR experiments and would be recommended for further
experimentation on the detection of Brucella cells using conventional PCR.
B. abortus 2308 and B. melitensis 16M in Sterile H2O
The first series of PCR were performed using DNA isolated from a known
amount of colony forming units (CFU) of both 2308 and 16M as template, as well as
using CFU as template using the Omp25 and Baily primers for both. The CFU were
diluted in sterile H2O for a series of ten 1:10 dilutions from the original 1x1010
concentration of 2308 CFU and eleven 1:10 dilutions from the original 1x1011
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Figure 10.
Agarose gel electrophoresis of the PCR amplification products of 16M DNA serially
diluted in sterile H2O using the ORF-944 region E primers.
The lane order for the 16M gels is as follows:
1. 1kb size standard marker
2. Positive RB51-QAE control
3. Negative control
4-9. RB51-QAE DNA concentrations from 107 CFU/μl – 102 CFU/μl

96

concentration of 16M CFU (both diluted to a final concentration of 1×101 CFU). A 1.0
μl sample of each CFU dilution was subjected to PCR using both primer sets. The rest of
the dilutions underwent the standard lab DNA isolation procedure described and the
resultant DNA isolates were subsequently amplified by PCR using both primer sets.
Using the Omp25 primers and 2308 CFU, positive identification was possible to
the 103 2308 CFU/μl H2O. Using the Baily primers and 2308 CFU, positive
identification was also possible to the 103 2308 CFU/μl H2O. Faint banding seen on the
gel in dilutions greater than 103 2308 CFU/μl H2O was rare and this was most likely due
to a contamination error. Using both the Omp25 and Baily primers and 16M CFU,
positive identification was possible to the 1x103 16M CFU/μl H2O. There were no faint
bands witnessed in dilutions greater than 1x103 16M CFU/μl H2O like those seen for
2308 (Figure 11).
Using the Omp25 primers and 2308 DNA isolates, positive identification was
possible for every dilution tested (1x109-1x1001 2308 DNA/100μl H2O). The same was
observed using the Baily primers and 2308 DNA isolates. For the DNA isolated from
16M, both the Omp25 and Baily primers produced positive banding for all dilutions
(1x1010-1x1001 16M DNA/100μl H2O) (Figure 12). Contamination was ruled out for all
PCR reactions due to the absence of a band in the negative control lane.
DNA Isolation Techniques for Whole Blood
Two DNA isolation techniques were tested for optimal DNA recovery from
samples of whole blood spiked with B. abortus 2308 and B. melitensis 16M. The first
was a standard procedure used in lab for DNA isolation from Brucella spp. CFU. The
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Figure 11.
Results of the agarose gel electrophoresis of the PCR amplification products of 2308 and
16M in sterile H2O using CFU as template and both primer sets.
The lane order for the 16M gels is as follows:
1. 1kb size standard marker
2. Negative control
3-13. 16M CFU concentrations from 109 CFU/μl – 0.1 CFU/μl
The lane order for the 2308 gels is as follows:
1. 1kb size standard marker
2. Negative control
3-13. 2308 CFU concentrations from 108 CFU/μl – 0.1 CFU/μl
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Figure 12.
Agarose gel electrophoresis of the PCR products of DNA isolated from ddH2O dilutions
of 2308 using the Omp25 primer set. These results were consistent with those observed
for the amplification of 2308 DNA using the Baily primers and for the amplification of
16M DNA across both primer sets as well.
The lane order for the 16M omp25 and Baily gels is as follows:
1. 1kb Marker
2. Negative control
3-12. DNA isolation concentrations from 108 CFU/μl – 1 CFU/10μl
The lane order for the 2308 omp 25 and Baily gels is as follows
1. 1kb Marker
2. Negative control
3-11. DNA isolation concentrations from 107 CFU/μl – 1 CFU/10μl
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second was the suggested procedure for DNA isolations from samples of whole blood.
Both procedures were taken from the Qiagen DNeasy kit manual.
The first DNA isolation procedure provided a greater output of isolated DNA, as
shown by higher detection capabilities when subjected to PCR amplification. As a result,
the remaining DNA isolations performed utilized the standard lab procedure first
described.
B. abortus 2308 and B. melitensis 16M in Whole Blood
Serial 1:10 dilutions were prepared similarly to the first series of PCR assays, but
using whole blood from a brucellosis negative goat in the place of sterile H2O. The CFU
were diluted in whole blood for a series of ten 1:10 dilutions from the original 1×1010
concentration of 2308 CFU and eleven 1:10 dilutions from the original 1×1011
concentration of 16M CFU. The dilutions underwent both the first and second DNA
isolation procedures described and the DNA isolates were amplified by PCR using both
primer sets. The DNA examined in these experiments was obtained through DNA
isolation of whole blood and CFU mixtures and at no time was DNA alone added to any
dilution of whole blood.
Using whole blood to dilute B. abortus 2308 and B. melitensis 16M CFU as
template for PCR using both primer sets proved unsuccessful for detection in any of the
dilutions tested. Elongation of thermal cycler protocols for both Omp25 and Baily
primers did not improve detection and no positive banding was observed on any of the
gels run for these assays (data not shown).
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The standard lab procedure for DNA isolation provided greater detection
capabilities than using CFU alone when testing whole blood dilutions spiked with 2308
and 16M. Using the B. melitensis 16M DNA isolated from CFU in whole blood, the
Baily primers provided a limit of detection down to the 1x103 original CFU dilution. The
Omp25 primers were not as effective for B. melitensis 16M DNA and provided positive
banding to the 1x104 original CFU dilution when diluted in whole blood. For the B.
abortus 2308 DNA isolates, both primer sets provided positive banding to the 1x102
original CFU dilution, but this band was extremely faint. For this reason, it was
concluded that the limit of detection for B. abortus 2308 DNA isolated from CFU in
whole blood was seen at 1x103 original CFU dilution (Figure 13).
The second procedure for DNA isolation was not as effective as the standard
procedure described above. For the 16M DNA isolates, both Omp25 and Baily primers
were able to provide a limit of detection of 1x106 original CFU concentration. For the
2308 DNA isolates, both Omp25 and Baily primers provided positive banding up to the
1x106 original CFU concentration. However, the band seen for a 1x106 CFU
concentration of B. abortus 2308 DNA was extremely faint for both primer sets, and was
not considered sufficiently visible for an absolute positive result. For this reason, it was
concluded that the limit of detection for B. abortus 2308 DNA using the standard lab
protocol for DNA isolation is 1x107 original CFU concentration in whole blood for both
Omp25 and Baily primer sets.
Both DNA isolation procedures performed for the 2308 and 16M dilutions in
whole blood exhibited inferior detection capabilities when compared to those observed
for 2308 and 16M dilutions in sterile H2O. It was noted during DNA isolation for both
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Figure 13.
Agarose gel electrophoresis of the PCR products of DNA isolated from dilutions of 2308
and 16M CFU in whole blood using the Baily and Omp25 primer sets.
The order of the lanes is as follows:
1. 1kb size standard marker
2. Negative control
3. DNA isolation concentrations from 108 CFU/μl – 1 CFU/10μl
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procedures that red blood cell lysis products tend to block flow through a spin column,
which may have inhibited the amount of DNA isolated from these samples. For this
reason, whole blood would not be considered as an ideal fluid for the detection of
Brucella cells, if present in the sample (Not pictured).
B. abortus 2308 and B. melitensis 16M in Plasma
Serial 1:10 dilutions were prepared in the same way as the whole blood series of
PCR assays, but using plasma from a brucellosis negative goat in the place of blood. The
B. melitensis 16M and B. abortus 2308 CFU were diluted similarly. The dilutions
underwent only the first standard DNA isolation procedure described and the DNA
isolates were amplified by PCR using both primer sets.
For the PCR amplification of B. melitensis 16M CFU, a limit of detection was
observed at a concentration of 1x105 CFU using both the Omp25 and Baily primers.
Using B. abortus 2308 CFU as template for both primer sets yielded a limit of detection
of 1x105 CFU (Figure 14).
Amplification of DNA isolated from plasma dilutions yielded positive detection
in both species of Brucella, in all dilutions, using both primer sets. No contamination was
detected, as the negative control lane did not produce banding. Based on these results, it
would be possible to detect DNA isolated from CFU of 16M or 2308, if present, in a
sample of plasma using the Omp25 and Baily primers for conventional PCR (Figure 15).
B. abortus 2308 and B. melitensis 16M in Serum
The PCR assays for serum spiked with 2308 and 16M CFU provided results
similar to those for 2308 and 16M CFU dilutions in sterile H2O for both primer sets.
Detection of CFU diluted in serum yielded a limit of 1x103 CFU/μl in both 16M and
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Figure 14.
Results of the agarose gel electrophoresis of the PCR amplification products of 2308 and
16M in plasma using CFU as template and both primer sets.
The lane order for the gels is as follows:
1. 1kb size standard marker
2. Negative control
3-12. CFU concentrations from 108 CFU/μl – 0.1 CFU/μl
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Figure 15.
Agarose gel electrophoresis of the PCR products of DNA isolated from dilutions of 16M
and 2308 CFU in plasma using the Baily and Omp25 primer sets. Detection is possible
in every dilution.
The order of the lanes for the Omp25 gels is as follows:
1. 1kb standard size marker
2. Negative control
3-11. DNA isolation concentrations from 107 CFU/μl –1 CFU/10μl
The order of the lanes for the Baily gels is as follows:
1. 1kb standard size marker
2. Negative control
3-12. DNA isolation concentrations from 108 CFU/μl –1 CFU/10μl
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2308 using both Omp25 and Baily primers (Figure 16). DNA isolated from serum
dilutions yielded positive detection following PCR amplification in all 16M and 2308
dilutions (1x109-1x101 original CFU concentration) using both primer sets (Figure 17).
These results show that it would be possible to detect 16M and 2308 CFU, if present, in a
serum sample using DNA isolation and conventional PCR using the Omp25 and Baily
primers.
B. abortus 2308 and B. melitensis 16M in Urine
The PCR assays for urine spiked with 2308 and 16M CFU provided results
similar to those for 2308 and 16M CFU dilutions in sterile H2O. Specifically, DNA
isolations performed on 2308 and 16M CFU diluted in urine provided positive banding in
every dilution (1x109-1x101 original CFU concentration) using both primer sets (Figure
18). Using urine spiked with 2308 and 16M CFU as direct template for PCR resulted in
positive visual identification up to the 1x105 original CFU dilution (1×103 CFU/μl) using
both primer sets, which is identical to the results observed using 2308 and 16M CFU
diluted in sterile H2O (Figure 19).DNA isolations performed using urine dilutions of
2308 and 16M provided complete detection, with banding in every dilution across both
primer sets. With these results, it would be possible to detect Brucella CFU in urine, if
present, using the Omp25 and Baily primers and conventional PCR techniques following
the isolation of DNA from the sample.

Discussion
This is the first known study to investigate the limit of detection when testing
bodily fluids for the presence of Brucella cells using conventional PCR. It is unknown
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Figure 16.
Agarose gel electrophoresis of the PCR products of 16M and 2308 CFU dilutions in
serum using the Omp25 and Baily primer sets. This limit of detection was consistent
across both species and primer sets.
The order of the lanes is as follows:
1. 1kb standard size marker
2. Negative control
3-12. CFU concentrations from 108 CFU/μl – 1 CFU/10 μl
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Figure 17.
Agarose gel electrophoresis of the PCR products of DNA isolated from dilutions of 16M
and 2308 CFU in serum using the Baily and Omp25 primer sets. Detection is possible in
every dilution.
The order of the lanes for every gel is as follows:
1. 1kb standard weight marker
2. Negative control
3-11. DNA isolation concentrations from 107 CFU/μl – 1 CFU/10μl
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Figure 18.
Agarose gel electrophoresis of the PCR products of 16M and 2308 CFU dilutions in urine
using the Baily and Omp25 primer sets. This limit of detection was consistent across
both species and primer sets.
The order of the lanes for each gel is as follows:
1. 1kb standard weight marker
2. Negative control
3-12. DNA isolation concentrations from 108 CFU/μl – 1 CFU/10μl
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Figure 19.
Agarose gel electrophoresis of the PCR products of DNA isolated from dilutions of 16M
and 2308 CFU in urine using the Omp25 and Baily primer sets. Detection is possible in
every dilution.
The order of the lanes is as follows:
1. 1kb standard size marker
2. Negative control
3-11. 16 M CFU concentrations from 107 CFU/μl – 1 CFU/10 μl
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what the content of bacteria is in an actual case sample at different stages of infection,
and further investigation would be needed to examine these quantities.
The results of each bodily fluid assay were compared to a control study performed
in sterile H2O using both B. melitensis 16M and B. abortus 2308 DNA isolations and
both primer sets. Detection was possible for DNA isolations from concentrations of each
species from 1x1010 CFU/ ml through 1x101 CFU/ ml for the PCR assays using known
concentrations of cells. An assay was performed using just CFU as template for PCR
(without DNA isolation) and the limit of detection for each species using each primer set
was observed at 1x105 CFU/ ml. For the quantified DNA isolated from an unknown
concentration of cells, a limit of detection for 16M using the Omp25 primers was found
to be 9.35x10-5 μg/μl and the limit of detection for 2308 using the Omp25 primers was
found to be 8.72x10-6 μg/μl. For the quantified DNA isolated from an unknown
concentration of cells, a limit of detection for B. abortus 2308 using the Baily primers
was found to be 8.72x10-8 μg/μl and the limit of detection for B. melitensis 16M using the
Baily primers was found to be 9.35x10-8 μg/μl. These preliminary findings were used to
compare each of the following assays to determine the effect of each bodily fluid on
DNA isolation and PCR amplification on detection capabilities using conventional PCR.
A limit of detection assay was also performed for the ORF-944 region E primers
for both 16M and RB51-QAE. This assay produced results similar to those observed for
the Omp25 primers for 16M and the limit of detection for RB51-QAE (4.0x10-6 μg/μl )
was similar to the limit of detection for 2308 using the Omp25 primers (8.72x10-6 μg/μl).
Based on these findings, it can be assumed that the detection of RB51-QAE using the
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ORF-944 primer set may be comparable to the limit of detection findings for 2308 using
the Omp25 primer set in the following experiments.
The optimization of thermal-cycler protocols has been a standard procedure for
many preliminary PCR assays, especially those using new primer sets. The addition of 5
cycles to each protocol increased amplification to a degree that improved detection
capabilities significantly. The following results are based on the elongated thermalcycler protocol.
Whole blood is used for culturing assays, and for this reason was the first fluid
tested in this study. It is easy to obtain through non-invasive procedures from humans or
animals, and animal slaughter is not required. However, there are several drawbacks to
using whole blood for PCR amplification of pathogen DNA. First, the erythrocytes
present in a whole blood sample interfere with standard DNA isolation techniques using a
spin column. The RBCs present in the sample can clog the spin column, inhibiting
efficient collection and reducing the amount of DNA present in the final isolate volume.
Second, some components of whole blood, such as hemoglobin, can inhibit amplification
by PCR.
Whole blood was not found to be an optimal candidate for detection of Brucella
in a blood sample. Using CFU of B. abortus 2308 and B. melitensis 16M in whole blood
as template for PCR amplification was not detectable using neither primer set in any of
the diliutions tested. For DNA isolated from whole blood dilutions, the limit of detection
was found at 1x103 CFU/ ml for 2308 using both primer sets and for 16M using the Baily
primers. The limit of detection for B. melitensis 16M using the Omp25 primers yielded a

112

limit of detection at 1x104 CFU/ ml. All results for DNA isolated from whole blood
dilutions show decreased detection capability when compared to controls.
The differences between procedure 1 and procedure 2 for DNA isolation from
whole blood provided an insight into the limitations of the Qiagen kit used. The main
difference between the two is that the lab procedure generally used employed a greater
number of cell lysis buffers for a greater period of time. Furthermore, a larger sample
could be examined using the laboratory technique and thus, a greater final volume of
Brucella-specific DNA could be obtained for study.
Plasma was chosen for investigation because plasma samples contain the buffy
coat, which is a layer of white cells found between the erythrocytes and plasma layers in
an anti-coagulation collection tube after settling of whole blood. Because Brucella are
sequestered into the macrophages for replication, studying this layer in plasma is of
importance. Plasma is a more fluid substance that generally does not interfere with DNA
isolation techniques. As with blood, it is also easy to obtain through non-invasive
procedures. Detection of B. melitensis 16M CFU was decreased to 1x107 CFU/ ml in
plasma when compared to controls. Although there still remain PCR-inhibiting factors in
plasma, there are far fewer than when compared to whole blood. Detection of Brucella
CFU in plasma was similar to controls and detection of DNA isolated from plasma
dilutions provided detection in all dilutions studied across both species and primer sets.
This provides evidence that plasma is an acceptable fluid for the use of Brucella cellular
detection when subjected to DNA isolation.
Serum has been tested widely in PCR investigations and thus, has been examined
here. The issue with using serum to diagnose brucellosis is that bacteria are largely
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absent from the serum following the bacteremic stage of infection. However, serum does
not appear to inhibit DNA isolation and the PCR-inhibitors found within this substance
are minimal. The assay exploring the detection capabilities of the Omp25 and Baily
primers of 16M and 2308 in serum produced results similar to those seen in the control
group and in the plasma group. Specifically, a limit of detection was observed at 1×103
CFU/μl for CFU and detection of isolated DNA was positive throughout every dilution
for both species of Brucella using both primer sets. This suggests that serum has minimal
inhibitions to DNA isolation and PCR amplification and it would be possible to detect
Brucella cells, if present, in a serum sample using conventional PCR.
Urine, even when concentrated, appeared to have the least inhibiting effects in
both DNA isolation and PCR, although crystal in urine have been shown to be inhibitive
to PCR in the past. The assays performed with urine dilutions provided results similar to
controls. DNA isolation provided complete detection in every dilution across both
species and primer sets. Urine has been examined in previous studies for the detection of
Brucella species by PCR. However, only two species of Brucella are shed in the urine
and neither is of any real threat to humans. Nevertheless, practical applications may be
potentially applied in the diagnosis of animals.
`

Ultimately, plasma, subjected to DNA isolation, is the best candidate for detection

of Brucella cells from a blood sample. Whole blood was found to be inhibitive of both
DNA isolation and PCR amplification. Brucella cells may not be present in the serum
following bacteremia and thus, there may be no CFU present for detection using PCR at
various stages of infection. Urine was the most efficient fluid in PCR assays and
provided results most similar to the control groups, but may be unconventional for
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practical applications. Furthermore, plasma contains the buffy coat layer, where Brucella
cells may reside within macrophages. DNA isolation provided superior detection when
compared to using CFU as template for all groups tested. Although this procedure takes
longer and requires more cost than using CFU alone, using CFU as template is not a
feasible method of accurate detection. Another factor to consider is the stage of infection
at which the blood sample is taken. For example, detection may be capable in serum if
taken while the subject or animal is bacteremic, otherwise Brucella cells may not be
present for detection. Periodic testing may also be an optimal route for the positive
identification of brucellosis in suspect infections.
These experiments show that in optimal conditions, it is possible to positively
identify Brucella present in a blood or urine sample using conventional PCR as a
diagnostic tool. Because this is the first series of experiments known to be performed to
study the limit of detection capable when using bodily fluids, this information can be of
great importance in furthering studies on detection of Brucella in a clinical setting using
PCR. If a reliable PCR technique, using either conventional or Real-Time methods,
could be implicated in endemic countries, diagnosis capabilities would be greatly
improved in both animals and humans. Not only would diagnosis be performed up to
four times more quickly, but the tests developed may be more sensitive as well. Further
studies are needed to fully develop an optimal and reliable PCR technique for such
purposes are ongoing.
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SUMMARY AND CONCLUSIONS
To better understand the role of a pathogen in disease, it is important to identify
and examine its virulence factors on both a genetic and protein level. Many methods
have been used to evaluate antigenic determinants and virulence genes of Brucella
species and their role in infection, including transposon and signature-tagged mutagenesis
(STM) (Ocampo-Sosa et al. 2008, Pei et al. 2007, Liautard et al. 2007, Zygmunt et al.
2006, Wu et al. 2006, Kahl-McDonagh ad Ficht 2006, Lestrate et al. 2000 & 2003, Hong
et al. 2000, Foulongne et al. 2000, Sangari et al. 1991, Allen et al. 1998, Smith et al.
1987), cellular immunoblotting (Brooks-Worrell et al. 1992a & 1992b), and deletion
mutants (Nijskens et al. 2008, Miyoshi et al. 2007, Perry 2007, Delpino et al. 2007,
Edmonds et al. 2002a 2002b 2001 & 2002, Phillips et al. 1997, Elzer et al. 1996 &1994).
Genomic mapping of several Brucella species has aided in the exploration of
virulence factors and their effects both in vivo and in vitro. The genome of B. melitensis
16M was completely sequenced by Vito G. DelVecchio et al. in 2002 and several other
strains have since been mapped from five species of Brucella. A putative hemagglutinin
was identified in B. melitensis (as well as B. ovis, with homologous sequences found in B.
suis and B. canis) that was not present in the B. abortus genome. The gene sequence for
this putative hemagglutinin was identified as Region E and hypothesized as a significant
virulence factor for B. melitensis.
Brucella hemagglutinins have been studied across several species and hosts and
the ability of Brucella species to agglutinate red blood cells of several hosts has been
documented (del C Rocha-Gracia 2002, Rocha et al. 1999, Zheludkov 1982, Diaz et al.
1967). In 1999 Rocha et al. described that Brucella strains are able to hemagglutinate
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human, hamster and rabbit red blood cells (RBC). From this experiment, an unnamed
41kD surface protein was identified as a possible hemagglutinin and eukaryotic cell
adhesion. More recently, del C Rocha-Gracia identified a specific hemagglutinin
(labeled SP29) in 2002 which is present on the surface of all Brucella strains tested.
SP29 is described as a 29kD surface protein and was found to agglutinate RBC samples
from human, rabbit, hamster, rat, and mouse sources.
These studies have supported the hypothesis that the region E protein has
hemagglutinative properties, is expressed as a cell surface protein, and shows aspects of
specificity toward a caprine host. Furthermore, it has been shown that the addition of
region E to RB51 increases the survivability and colonization of RB51 in the goat model,
meriting further investigation into the potential development of an improved vaccine for
brucellosis. In vivo studies showed that the region E protein induces the production of
anti-region E antibodies in the caprine host as well as an increase in the production of
Brucella-specific antibodies following inoculation, when compared to the parental strain.
PCR amplification data obtained using primers to the region E gene and the isolated
DNA of RB51-QAE and 16M have suggested that it would be possible to use
conventional PCR to detect species of Brucella that carry the region E gene sequence.
The detection capabilities of the region E primers were similar to those observed for the
Omp25 and Baily primers designed to detect all species of Brucella. Although not
confirmed, it is suggested at the region E primers, having performed similarly in control
assays, would also be effective in detecting region E-encoding Brucella species in bodily
fluids. The results of conventional PCR assays using Brucella cells diluted in various
bodily fluids supported the hypothesis that it is possible to detect the presence of Brucella
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CFU in bodily fluids using conventional PCR. Additional research would be needed to
assess the full potential of using the region E, Omp25, and Baily primers to successfully
detect Brucella cells in bodily fluids for diagnostic purposes. These results merit further
research into both the potential role of region E in improving the efficacy of the RB51
vaccine, and the use of conventional PCR as a diagnostic tool for the purposes of
strengthening brucellosis eradication efforts worldwide.
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